ID   CAH2_HUMAN              Reviewed;         260 AA.
AC   P00918; B2R7G8; Q6FI12; Q96ET9;
DT   21-JUL-1986, integrated into UniProtKB/Swiss-Prot.
DT   23-JAN-2007, sequence version 2.
DT   10-MAY-2017, entry version 218.
DE   RecName: Full=Carbonic anhydrase 2;
DE            EC=4.2.1.1;
DE   AltName: Full=Carbonate dehydratase II;
DE   AltName: Full=Carbonic anhydrase C;
DE            Short=CAC;
DE   AltName: Full=Carbonic anhydrase II;
DE            Short=CA-II;
GN   Name=CA2;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=3108857; DOI=10.1093/nar/15.11.4687;
RA   Montgomery J.C., Venta P.J., Tashian R.E., Hewett-Emmett D.;
RT   "Nucleotide sequence of human liver carbonic anhydrase II cDNA.";
RL   Nucleic Acids Res. 15:4687-4687(1987).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=3121496; DOI=10.1016/0888-7543(87)90008-5;
RA   Murakami H., Marelich G.P., Grubb J.H., Kyle J.W., Sly W.S.;
RT   "Cloning, expression, and sequence homologies of cDNA for human
RT   carbonic anhydrase II.";
RL   Genomics 1:159-166(1987).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RA   Halleck A., Ebert L., Mkoundinya M., Schick M., Eisenstein S.,
RA   Neubert P., Kstrang K., Schatten R., Shen B., Henze S., Mar W.,
RA   Korn B., Zuo D., Hu Y., LaBaer J.;
RT   "Cloning of human full open reading frames in Gateway(TM) system entry
RT   vector (pDONR201).";
RL   Submitted (JUN-2004) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Urinary bladder;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Ovary;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7]
RP   PROTEIN SEQUENCE OF 2-260, CLEAVAGE OF INITIATOR METHIONINE, AND
RP   ACETYLATION AT SER-2.
RX   PubMed=4207120;
RA   Lin K.-T.D., Deutsch H.F.;
RT   "Human carbonic anhydrases. XII. The complete primary structure of the
RT   C isozyme.";
RL   J. Biol. Chem. 249:2329-2337(1974).
RN   [8]
RP   PROTEIN SEQUENCE OF 2-260.
RX   PubMed=823150;
RA   Henderson L.E., Henriksson D., Nyman P.O.;
RT   "Primary structure of human carbonic anhydrase C.";
RL   J. Biol. Chem. 251:5457-5463(1976).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-77.
RX   PubMed=3000449; DOI=10.1016/0167-4781(85)90006-5;
RA   Venta P.J., Montgomery J.C., Hewett-Emmett D., Tashian R.E.;
RT   "Comparison of the 5' regions of human and mouse carbonic anhydrase II
RT   genes and identification of possible regulatory elements.";
RL   Biochim. Biophys. Acta 826:195-201(1985).
RN   [10]
RP   INTERACTION WITH SLC4A4.
RX   PubMed=14567693; DOI=10.1021/bi0353124;
RA   Alvarez B.V., Loiselle F.B., Supuran C.T., Schwartz G.J., Casey J.R.;
RT   "Direct extracellular interaction between carbonic anhydrase IV and
RT   the human NBC1 sodium/bicarbonate co-transporter.";
RL   Biochemistry 42:12321-12329(2003).
RN   [11]
RP   INTERACTION WITH SLC4A7.
RX   PubMed=14736710; DOI=10.1152/ajpcell.00382.2003;
RA   Loiselle F.B., Morgan P.E., Alvarez B.V., Casey J.R.;
RT   "Regulation of the human NBC3 Na+/HCO3- cotransporter by carbonic
RT   anhydrase II and PKA.";
RL   Am. J. Physiol. 286:C1423-C1433(2004).
RN   [12]
RP   INTERACTION WITH SLC4A4.
RX   PubMed=15218065; DOI=10.1113/jphysiol.2004.065110;
RA   Pushkin A., Abuladze N., Gross E., Newman D., Tatishchev S., Lee I.,
RA   Fedotoff O., Bondar G., Azimov R., Ngyuen M., Kurtz I.;
RT   "Molecular mechanism of kNBC1-carbonic anhydrase II interaction in
RT   proximal tubule cells.";
RL   J. Physiol. (Lond.) 559:55-65(2004).
RN   [13]
RP   FUNCTION, INTERACTION WITH SLC26A6, AND SUBCELLULAR LOCATION.
RX   PubMed=15990874; DOI=10.1038/sj.emboj.7600736;
RA   Alvarez B.V., Vilas G.L., Casey J.R.;
RT   "Metabolon disruption: a mechanism that regulates bicarbonate
RT   transport.";
RL   EMBO J. 24:2499-2511(2005).
RN   [14]
RP   ENZYME REGULATION.
RX   PubMed=17314045; DOI=10.1016/j.bmcl.2007.01.113;
RA   Temperini C., Innocenti A., Guerri A., Scozzafava A., Rusconi S.,
RA   Supuran C.T.;
RT   "Phosph(on)ate as a zinc-binding group in metalloenzyme inhibitors: X-
RT   ray crystal structure of the antiviral drug foscarnet complexed to
RT   human carbonic anhydrase I.";
RL   Bioorg. Med. Chem. Lett. 17:2210-2215(2007).
RN   [15]
RP   BIOPHYSICOCHEMICAL PROPERTIES, AND ENZYME REGULATION.
RX   PubMed=18618712; DOI=10.1002/prot.22144;
RA   Di Fiore A., Monti S.M., Hilvo M., Parkkila S., Romano V., Scaloni A.,
RA   Pedone C., Scozzafava A., Supuran C.T., De Simone G.;
RT   "Crystal structure of human carbonic anhydrase XIII and its complex
RT   with the inhibitor acetazolamide.";
RL   Proteins 74:164-175(2009).
RN   [16]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [17]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-165 AND SER-172, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [18]
RP   X-RAY CRYSTALLOGRAPHY (2.0 ANGSTROMS).
RX   PubMed=4621826;
RA   Liljas A., Kannan K.K., Bergsten P.-C., Waara I., Fridborg K.,
RA   Strandberg B., Carlbom U., Jaerup L., Loevgren S., Petef M.;
RT   "Crystal structure of human carbonic anhydrase C.";
RL   Nature New Biol. 235:131-137(1972).
RN   [19]
RP   X-RAY CRYSTALLOGRAPHY (2.00 ANGSTROMS) IN COMPLEX WITH ZINC ION.
RX   PubMed=3151019; DOI=10.1002/prot.340040406;
RA   Eriksson A.E., Jones T.A., Liljas A.;
RT   "Refined structure of human carbonic anhydrase II at 2.0-A
RT   resolution.";
RL   Proteins 4:274-282(1988).
RN   [20]
RP   X-RAY CRYSTALLOGRAPHY (1.90 ANGSTROMS) IN COMPLEX WITH ZINC ION AND
RP   INHIBITORS.
RX   PubMed=3151020; DOI=10.1002/prot.340040407;
RA   Eriksson A.E., Kylsten P.M., Jones T.A., Liljas A.;
RT   "Crystallographic studies of inhibitor binding sites in human carbonic
RT   anhydrase II: a pentacoordinated binding of the SCN-ion to the zinc at
RT   high pH.";
RL   Proteins 4:283-293(1988).
RN   [21]
RP   X-RAY CRYSTALLOGRAPHY (2.10 ANGSTROMS) OF MUTANT SER-199 IN COMPLEX
RP   WITH ZINC ION, MUTAGENESIS OF THR-199, AND BIOPHYSICOCHEMICAL
RP   PROPERTIES.
RX   PubMed=1909891; DOI=10.1021/bi00102a005;
RA   Krebs J.F., Fierke C.A., Alexander R.S., Christianson D.W.;
RT   "Conformational mobility of His-64 in the Thr-200TO: human carbonic
RT   anhydrase II.";
RL   Biochemistry 30:9153-9160(1991).
RN   [22]
RP   X-RAY CRYSTALLOGRAPHY (2.10 ANGSTROMS) OF MUTANTS PHE-142; TYR-142 AND
RP   HIS-142 IN COMPLEX WITH INHIBITORS, AND MUTAGENESIS OF VAL-142.
RX   PubMed=1932029; DOI=10.1021/bi00110a008;
RA   Alexander R.S., Nair S.K., Christianson D.W.;
RT   "Engineering the hydrophobic pocket of carbonic anhydrase II.";
RL   Biochemistry 30:11064-11072(1991).
RN   [23]
RP   X-RAY CRYSTALLOGRAPHY (2.40 ANGSTROMS) OF MUTANT ALA-121, MUTAGENESIS
RP   OF VAL-121, ENZYME REGULATION, AND BIOPHYSICOCHEMICAL PROPERTIES.
RX   PubMed=1910042;
RA   Nair S.K., Calderone T.L., Christianson D.W., Fierke C.A.;
RT   "Altering the mouth of a hydrophobic pocket. Structure and kinetics of
RT   human carbonic anhydrase II mutants at residue Val-121.";
RL   J. Biol. Chem. 266:17320-17325(1991).
RN   [24]
RP   X-RAY CRYSTALLOGRAPHY (1.90 ANGSTROMS) IN COMPLEX WITH ZINC ION AND
RP   INHIBITORS, AND ENZYME REGULATION.
RX   PubMed=1336460; DOI=10.1111/j.1432-1033.1992.tb17490.x;
RA   Mangani S., Haakansson K.;
RT   "Crystallographic studies of the binding of protonated and
RT   unprotonated inhibitors to carbonic anhydrase using hydrogen sulphide
RT   and nitrate anions.";
RL   Eur. J. Biochem. 210:867-871(1992).
RN   [25]
RP   X-RAY CRYSTALLOGRAPHY (1.54 ANGSTROMS) IN COMPLEX WITH ZINC ION AND
RP   INHIBITORS.
RX   PubMed=1433293; DOI=10.1016/0022-2836(92)90531-N;
RA   Haakansson K., Carlsson M., Svensson L.A., Liljas A.;
RT   "Structure of native and apo carbonic anhydrase II and structure of
RT   some of its anion-ligand complexes.";
RL   J. Mol. Biol. 227:1192-1204(1992).
RN   [26]
RP   X-RAY CRYSTALLOGRAPHY (1.88 ANGSTROMS) IN COMPLEX WITH COBALT ION AND
RP   BICARBONATE.
RX   PubMed=1474587; DOI=10.1016/0022-2836(92)90327-G;
RA   Haakansson K., Wehnert A.;
RT   "Structure of cobalt carbonic anhydrase complexed with bicarbonate.";
RL   J. Mol. Biol. 228:1212-1218(1992).
RN   [27]
RP   X-RAY CRYSTALLOGRAPHY (2.30 ANGSTROMS) OF MUTANT CYS-94 IN COMPLEX
RP   WITH ZINC ION, AND MUTAGENESIS OF HIS-94.
RX   PubMed=8431430; DOI=10.1021/bi00057a015;
RA   Alexander R.S., Kiefer L.L., Fierke C.A., Christianson D.W.;
RT   "Engineering the zinc binding site of human carbonic anhydrase II:
RT   structure of the His-94-->Cys apoenzyme in a new crystalline form.";
RL   Biochemistry 32:1510-1518(1993).
RN   [28]
RP   X-RAY CRYSTALLOGRAPHY (2.00 ANGSTROMS) OF MUTANT ALA-197; GLU-197;
RP   HIS-197 AND ARG-197, AND MUTAGENESIS OF LEU-197.
RX   PubMed=8485129; DOI=10.1021/bi00068a005;
RA   Nair S.K., Christianson D.W.;
RT   "Structural consequences of hydrophilic amino acid substitutions in
RT   the hydrophobic pocket of human carbonic anhydrase II.";
RL   Biochemistry 32:4506-4514(1993).
RN   [29]
RP   X-RAY CRYSTALLOGRAPHY (2.10 ANGSTROMS) OF MUTANT CYS-198 IN COMPLEX
RP   WITH ZINC ION, AND MUTAGENESIS OF THR-198.
RX   PubMed=8399159; DOI=10.1021/bi00089a005;
RA   Ippolito J.A., Christianson D.W.;
RT   "Structure of an engineered His3Cys zinc binding site in human
RT   carbonic anhydrase II.";
RL   Biochemistry 32:9901-9905(1993).
RN   [30]
RP   X-RAY CRYSTALLOGRAPHY (1.70 ANGSTROMS) OF MUTANT ALA-201 IN COMPLEX
RP   WITH ZINC ION, AND MUTAGENESIS OF PRO-201.
RX   PubMed=8218160; DOI=10.1021/bi00092a003;
RA   Tweedy N.B., Nair S.K., Paterno S.A., Fierke C.A., Christianson D.W.;
RT   "Structure and energetics of a non-proline cis-peptidyl linkage in a
RT   proline-202-->alanine carbonic anhydrase II variant.";
RL   Biochemistry 32:10944-10949(1993).
RN   [31]
RP   X-RAY CRYSTALLOGRAPHY (1.80 ANGSTROMS) IN COMPLEX WITH ZINC ION AND
RP   INHIBITORS.
RX   PubMed=8482389; DOI=10.1016/0014-5793(93)81565-H;
RA   Joensson B.M., Haakansson K., Liljas A.;
RT   "The structure of human carbonic anhydrase II in complex with bromide
RT   and azide.";
RL   FEBS Lett. 322:186-190(1993).
RN   [32]
RP   X-RAY CRYSTALLOGRAPHY (2.25 ANGSTROMS) OF MUTANT VAL-198 IN COMPLEX
RP   WITH ZINC ION AND INHIBITORS, MUTAGENESIS OF THR-198, AND
RP   BIOPHYSICOCHEMICAL PROPERTIES.
RX   PubMed=8262987;
RA   Krebs J.F., Ippolito J.A., Christianson D.W., Fierke C.A.;
RT   "Structural and functional importance of a conserved hydrogen bond
RT   network in human carbonic anhydrase II.";
RL   J. Biol. Chem. 268:27458-27466(1993).
RN   [33]
RP   X-RAY CRYSTALLOGRAPHY (1.90 ANGSTROMS) IN COMPLEX WITH INHIBITOR AND
RP   ZINC ION.
RX   PubMed=8331673; DOI=10.1006/jmbi.1993.1365;
RA   Mangani S., Liljas A.;
RT   "Crystal structure of the complex between human carbonic anhydrase II
RT   and the aromatic inhibitor 1,2,4-triazole.";
RL   J. Mol. Biol. 232:9-14(1993).
RN   [34]
RP   X-RAY CRYSTALLOGRAPHY (1.90 ANGSTROMS) OF MUTANT HIS-199 IN COMPLEX
RP   WITH BICARBONATE AND ZINC ION, AND MUTAGENESIS OF THR-199.
RX   PubMed=8451242; DOI=10.1002/prot.340150110;
RA   Xue Y., Vidgren J., Svensson L.A., Liljas A., Jonsson B.H.,
RA   Lindskog S.;
RT   "Crystallographic analysis of Thr-200-->His human carbonic anhydrase
RT   II and its complex with the substrate, HCO3-.";
RL   Proteins 15:80-87(1993).
RN   [35]
RP   X-RAY CRYSTALLOGRAPHY (1.70 ANGSTROMS) OF MUTANTS IN COMPLEX WITH
RP   BICARBONATE AND ZINC ION, AND MUTAGENESIS OF GLU-106 AND THR-198.
RX   PubMed=7901850; DOI=10.1002/prot.340170112;
RA   Xue Y., Liljas A., Jonsson B.H., Lindskog S.;
RT   "Structural analysis of the zinc hydroxide-Thr-199-Glu-106 hydrogen-
RT   bond network in human carbonic anhydrase II.";
RL   Proteins 17:93-106(1993).
RN   [36]
RP   X-RAY CRYSTALLOGRAPHY (1.80 ANGSTROMS) IN COMPLEX WITH COBALT; COPPER;
RP   NICKEL AND MANGANESE IONS.
RX   PubMed=15299481; DOI=10.1107/S0907444993008790;
RA   Haakansson K., Wehnert A., Liljas A.;
RT   "X-ray analysis of metal-substituted human carbonic anhydrase II
RT   derivatives.";
RL   Acta Crystallogr. D 50:93-100(1994).
RN   [37]
RP   X-RAY CRYSTALLOGRAPHY (1.90 ANGSTROMS) MUTANT GLN-106 IN COMPLEX WITH
RP   THE INHIBITOR ACETATE, AND MUTAGENESIS OF GLU-106.
RX   PubMed=15299482; DOI=10.1107/S0907444993009667;
RA   Haakansson K., Briand C., Zaitsev V., Xue Y., Liljas A.;
RT   "Wild-type and E106Q mutant carbonic anhydrase complexed with
RT   acetate.";
RL   Acta Crystallogr. D 50:101-104(1994).
RN   [38]
RP   X-RAY CRYSTALLOGRAPHY (2.20 ANGSTROMS) OF 2-259 OF MUTANTS ALA-94;
RP   CYS-94; CYS-96; CYS-119 AND ASP-119 IN COMPLEX WITH ZINC ION.
RX   PubMed=7803386; DOI=10.1021/bi00255a004;
RA   Ippolito J.A., Christianson D.W.;
RT   "Structural consequences of redesigning a protein-zinc binding site.";
RL   Biochemistry 33:15241-15249(1994).
RN   [39]
RP   X-RAY CRYSTALLOGRAPHY (1.90 ANGSTROMS) IN COMPLEX WITH THE INHIBITOR
RP   TRIFLUOROMETHANE SULPHONAMIDE.
RX   PubMed=8070585; DOI=10.1016/0014-5793(94)00798-5;
RA   Haakansson K., Liljas A.;
RT   "The structure of a complex between carbonic anhydrase II and a new
RT   inhibitor, trifluoromethane sulphonamide.";
RL   FEBS Lett. 350:319-322(1994).
RN   [40]
RP   X-RAY CRYSTALLOGRAPHY (1.60 ANGSTROMS) IN COMPLEX WITH INHIBITORS.
RX   PubMed=8142888; DOI=10.1002/pro.5560030115;
RA   Smith G.M., Alexander R.S., Christianson D.W., McKeever B.M.,
RA   Ponticello G.S., Springer J.P., Randall W.C., Baldwin J.J.,
RA   Habecker C.N.;
RT   "Positions of His-64 and a bound water in human carbonic anhydrase II
RT   upon binding three structurally related inhibitors.";
RL   Protein Sci. 3:118-125(1994).
RN   [41]
RP   X-RAY CRYSTALLOGRAPHY (1.90 ANGSTROMS) OF MUTANTS ARG-197; ASP-197 AND
RP   PHE-197 IN COMPLEX WITH THE INHIBITOR ACETAZOLAMIDE.
RX   PubMed=7696263; DOI=10.1021/bi00012a016;
RA   Nair S.K., Krebs J.F., Christianson D.W., Fierke C.A.;
RT   "Structural basis of inhibitor affinity to variants of human carbonic
RT   anhydrase II.";
RL   Biochemistry 34:3981-3989(1995).
RN   [42]
RP   X-RAY CRYSTALLOGRAPHY (1.90 ANGSTROMS) IN COMPLEX WITH INHIBITORS.
RX   PubMed=7608893; DOI=10.1021/jm00013a004;
RA   Boriack P.A., Christianson D.W., Kingery-Wood J., Whitesides G.M.;
RT   "Secondary interactions significantly removed from the sulfonamide
RT   binding pocket of carbonic anhydrase II influence inhibitor binding
RT   constants.";
RL   J. Med. Chem. 38:2286-2291(1995).
RN   [43]
RP   X-RAY CRYSTALLOGRAPHY (2.20 ANGSTROMS) OF MUTANTS ASP-198; GLU-198 AND
RP   HIS-198 IN COMPLEX WITH ZINC ION, MUTAGENESIS OF THR-198, AND
RP   BIOPHYSICOCHEMICAL PROPERTIES.
RX   PubMed=7761440; DOI=10.1073/pnas.92.11.5017;
RA   Ippolito J.A., Baird T.T. Jr., McGee S.A., Christianson D.W.,
RA   Fierke C.A.;
RT   "Structure-assisted redesign of a protein-zinc-binding site with
RT   femtomolar affinity.";
RL   Proc. Natl. Acad. Sci. U.S.A. 92:5017-5021(1995).
RN   [44]
RP   X-RAY CRYSTALLOGRAPHY (1.80 ANGSTROMS) OF THE MUTANT GLN-117 IN
RP   COMPLEX WITH ZINC ION AND THE INHIBITOR ACETAZOLAMIDE, AND MUTAGENESIS
RP   OF GLU-117.
RX   PubMed=8639494; DOI=10.1021/bi9526692;
RA   Huang C.C., Lesburg C.A., Kiefer L.L., Fierke C.A., Christianson D.W.;
RT   "Reversal of the hydrogen bond to zinc ligand histidine-119
RT   dramatically diminishes catalysis and enhances metal equilibration
RT   kinetics in carbonic anhydrase II.";
RL   Biochemistry 35:3439-3446(1996).
RN   [45]
RP   X-RAY CRYSTALLOGRAPHY (1.90 ANGSTROMS) OF MUTANTS GLY-65; HIS-65;
RP   LEU-65; PHE-65; SER-65 AND THR-65 IN COMPLEX WITH ZINC ION.
RX   PubMed=8987974; DOI=10.1021/bi9617872;
RA   Scolnick L.R., Christianson D.W.;
RT   "X-ray crystallographic studies of alanine-65 variants of carbonic
RT   anhydrase II reveal the structural basis of compromised proton
RT   transfer in catalysis.";
RL   Biochemistry 35:16429-16434(1996).
RN   [46]
RP   X-RAY CRYSTALLOGRAPHY (2.10 ANGSTROMS) IN COMPLEX WITH THE INHIBITOR
RP   DANSYLAMIDE.
RX   PubMed=8557623; DOI=10.1074/jbc.271.2.1003;
RA   Nair S.K., Elbaum D., Christianson D.W.;
RT   "Unexpected binding mode of the sulfonamide fluorophore 5-
RT   dimethylamino-1-naphthalene sulfonamide to human carbonic anhydrase
RT   II. Implications for the development of a zinc biosensor.";
RL   J. Biol. Chem. 271:1003-1007(1996).
RN   [47]
RP   X-RAY CRYSTALLOGRAPHY (2.00 ANGSTROMS) IN COMPLEX WITH THE ACTIVATOR
RP   HISTAMINE, AND ENZYME REGULATION.
RX   PubMed=9265618; DOI=10.1021/bi970760v;
RA   Briganti F., Mangani S., Orioli P., Scozzafava A., Vernaglione G.,
RA   Supuran C.T.;
RT   "Carbonic anhydrase activators: X-ray crystallographic and
RT   spectroscopic investigations for the interaction of isozymes I and II
RT   with histamine.";
RL   Biochemistry 36:10384-10392(1997).
RN   [48]
RP   X-RAY CRYSTALLOGRAPHY (1.85 ANGSTROMS) OF MUTANTS ASN-94; ASN-119 AND
RP   GLN-119 IN COMPLEX WITH ZINC ION, MUTAGENESIS OF HIS-94 AND HIS-119,
RP   AND BIOPHYSICOCHEMICAL PROPERTIES.
RX   PubMed=9398308; DOI=10.1021/bi971296x;
RA   Lesburg C.A., Huang C., Christianson D.W., Fierke C.A.;
RT   "Histidine --> carboxamide ligand substitutions in the zinc binding
RT   site of carbonic anhydrase II alter metal coordination geometry but
RT   retain catalytic activity.";
RL   Biochemistry 36:15780-15791(1997).
RN   [49]
RP   X-RAY CRYSTALLOGRAPHY (2.25 ANGSTROMS) IN COMPLEX WITH THE INHIBITOR
RP   BRINZOLAMIDE.
RX   PubMed=9541386; DOI=10.1002/pro.5560070303;
RA   Stams T., Chen Y., Boriack-Sjodin P.A., Hurt J.D., Liao J., May J.A.,
RA   Dean T., Laipis P., Silverman D.N., Christianson D.W.;
RT   "Structures of murine carbonic anhydrase IV and human carbonic
RT   anhydrase II complexed with brinzolamide: molecular basis of isozyme-
RT   drug discrimination.";
RL   Protein Sci. 7:556-563(1998).
RN   [50]
RP   X-RAY CRYSTALLOGRAPHY (2.10 ANGSTROMS) IN COMPLEX WITH SULFONAMIDE
RP   INHIBITORS AND ZINC ION.
RX   PubMed=9865942; DOI=10.1002/pro.5560071201;
RA   Boriack-Sjodin P.A., Zeitlin S., Chen H.H., Crenshaw L., Gross S.,
RA   Dantanarayana A., Delgado P., May J.A., Dean T., Christianson D.W.;
RT   "Structural analysis of inhibitor binding to human carbonic anhydrase
RT   II.";
RL   Protein Sci. 7:2483-2489(1998).
RN   [51]
RP   X-RAY CRYSTALLOGRAPHY (1.85 ANGSTROMS) IN COMPLEX WITH CYANAMIDE AND
RP   SUBSTRATE, FUNCTION, AND BIOPHYSICOCHEMICAL PROPERTIES.
RX   PubMed=10550681; DOI=10.1007/s007750050375;
RA   Briganti F., Mangani S., Scozzafava A., Vernaglione G., Supuran C.T.;
RT   "Carbonic anhydrase catalyzes cyanamide hydration to urea: is it
RT   mimicking the physiological reaction?";
RL   J. Biol. Inorg. Chem. 4:528-536(1999).
RN   [52]
RP   X-RAY CRYSTALLOGRAPHY (1.90 ANGSTROMS) IN COMPLEX WITH CYANAMIDE.
RX   PubMed=11015219; DOI=10.1021/bi000937c;
RA   Guerri A., Briganti F., Scozzafava A., Supuran C.T., Mangani S.;
RT   "Mechanism of cyanamide hydration catalyzed by carbonic anhydrase II
RT   suggested by cryogenic X-ray diffraction.";
RL   Biochemistry 39:12391-12397(2000).
RN   [53]
RP   X-RAY CRYSTALLOGRAPHY (1.50 ANGSTROMS) OF MUTANTS ILE-93/MET-95/VAL-97
RP   AND SER-93/LEU-95/MET-97 IN COMPLEX WITH COBALT; COPPER AND ZINC IONS.
RX   PubMed=11076507; DOI=10.1021/bi001649j;
RA   Cox J.D., Hunt J.A., Compher K.M., Fierke C.A., Christianson D.W.;
RT   "Structural influence of hydrophobic core residues on metal binding
RT   and specificity in carbonic anhydrase II.";
RL   Biochemistry 39:13687-13694(2000).
RN   [54]
RP   X-RAY CRYSTALLOGRAPHY (1.60 ANGSTROMS) OF THE MUTANT ALA-64 IN COMPLEX
RP   WITH 4-METHYLIMIDAZOLE, AND MUTAGENESIS OF HIS-64.
RX   PubMed=11327835; DOI=10.1021/bi002295z;
RA   Duda D., Tu C., Qian M., Laipis P., Agbandje-McKenna M.,
RA   Silverman D.N., McKenna R.;
RT   "Structural and kinetic analysis of the chemical rescue of the proton
RT   transfer function of carbonic anhydrase II.";
RL   Biochemistry 40:1741-1748(2001).
RN   [55]
RP   X-RAY CRYSTALLOGRAPHY (1.80 ANGSTROMS) OF MUTANT VAL-130 IN COMPLEX
RP   WITH FLUOROAROMATIC INHIBITORS.
RX   PubMed=11572683; DOI=10.1021/ja011034p;
RA   Kim C.Y., Chandra P.P., Jain A., Christianson D.W.;
RT   "Fluoroaromatic-fluoroaromatic interactions between inhibitors bound
RT   in the crystal lattice of human carbonic anhydrase II.";
RL   J. Am. Chem. Soc. 123:9620-9627(2001).
RN   [56]
RP   X-RAY CRYSTALLOGRAPHY (2.10 ANGSTROMS) IN COMPLEX WITH THE INHIBITOR
RP   SUGAR SULFAMATE RWJ-37497, AND ENZYME REGULATION.
RX   PubMed=11802772; DOI=10.1042/0264-6021:3610437;
RA   Recacha R., Costanzo M.J., Maryanoff B.E., Chattopadhyay D.;
RT   "Crystal structure of human carbonic anhydrase II complexed with an
RT   anti-convulsant sugar sulphamate.";
RL   Biochem. J. 361:437-441(2002).
RN   [57]
RP   X-RAY CRYSTALLOGRAPHY (1.75 ANGSTROMS) OF THE MUTANT PRO-198/SER-205
RP   IN COMPLEX WITH BICARBONATE AND INHIBITORS, AND MUTAGENESIS OF
RP   THR-198.
RX   PubMed=12056894; DOI=10.1021/bi020053o;
RA   Huang S., Sjoeblom B., Sauer-Eriksson A.E., Jonsson B.H.;
RT   "Organization of an efficient carbonic anhydrase: implications for the
RT   mechanism based on structure-function studies of a T199P/C206S
RT   mutant.";
RL   Biochemistry 41:7628-7635(2002).
RN   [58]
RP   X-RAY CRYSTALLOGRAPHY (2.30 ANGSTROMS) OF THE MUTANT HIS-7, AND
RP   MUTAGENESIS OF TYR-7.
RX   PubMed=12171926; DOI=10.1074/jbc.M205791200;
RA   Tu C., Qian M., An H., Wadhwa N.R., Duda D., Yoshioka C., Pathak Y.,
RA   McKenna R., Laipis P.J., Silverman D.N.;
RT   "Kinetic analysis of multiple proton shuttles in the active site of
RT   human carbonic anhydrase.";
RL   J. Biol. Chem. 277:38870-38876(2002).
RN   [59]
RP   X-RAY CRYSTALLOGRAPHY (1.93 ANGSTROMS) IN COMPLEX WITH INHIBITORS, AND
RP   FUNCTION.
RX   PubMed=11831900; DOI=10.1021/jm010163d;
RA   Kim C.Y., Whittington D.A., Chang J.S., Liao J., May J.A.,
RA   Christianson D.W.;
RT   "Structural aspects of isozyme selectivity in the binding of
RT   inhibitors to carbonic anhydrases II and IV.";
RL   J. Med. Chem. 45:888-893(2002).
RN   [60]
RP   X-RAY CRYSTALLOGRAPHY (2.25 ANGSTROMS) IN COMPLEX WITH INHIBITORS.
RX   PubMed=12166932; DOI=10.1021/jm011112j;
RA   Grueneberg S., Stubbs M.T., Klebe G.;
RT   "Successful virtual screening for novel inhibitors of human carbonic
RT   anhydrase: strategy and experimental confirmation.";
RL   J. Med. Chem. 45:3588-3602(2002).
RN   [61]
RP   X-RAY CRYSTALLOGRAPHY (1.94 ANGSTROMS) IN COMPLEX WITH INHIBITORS.
RX   PubMed=11818565; DOI=10.1073/pnas.032673399;
RA   Grzybowski B.A., Ishchenko A.V., Kim C.Y., Topalov G., Chapman R.,
RA   Christianson D.W., Whitesides G.M., Shakhnovich E.I.;
RT   "Combinatorial computational method gives new picomolar ligands for a
RT   known enzyme.";
RL   Proc. Natl. Acad. Sci. U.S.A. 99:1270-1273(2002).
RN   [62]
RP   X-RAY CRYSTALLOGRAPHY (1.05 ANGSTROMS) OF THE MUTANT ALA-64 IN COMPLEX
RP   WITH THE INHIBITOR 4-METHYLIMIDAZOLE AND ZINC ION.
RX   PubMed=12499545;
RA   Duda D., Govindasamy L., Agbandje-McKenna M., Tu C., Silverman D.N.,
RA   McKenna R.;
RT   "The refined atomic structure of carbonic anhydrase II at 1.05 A
RT   resolution: implications of chemical rescue of proton transfer.";
RL   Acta Crystallogr. D 59:93-104(2003).
RN   [63]
RP   X-RAY CRYSTALLOGRAPHY (1.50 ANGSTROMS) IN COMPLEX WITH INHIBITORS, AND
RP   ENZYME REGULATION.
RX   PubMed=14736236; DOI=10.1021/jm030912m;
RA   Weber A., Casini A., Heine A., Kuhn D., Supuran C.T., Scozzafava A.,
RA   Klebe G.;
RT   "Unexpected nanomolar inhibition of carbonic anhydrase by COX-2-
RT   selective celecoxib: new pharmacological opportunities due to related
RT   binding site recognition.";
RL   J. Med. Chem. 47:550-557(2004).
RN   [64]
RP   X-RAY CRYSTALLOGRAPHY (1.95 ANGSTROMS) IN COMPLEX WITH THE ANTI-CANCER
RP   AGENT 667-COUMATE.
RX   PubMed=15453828; DOI=10.1042/BJ20041037;
RA   Lloyd M.D., Pederick R.L., Natesh R., Woo L.W., Purohit A., Reed M.J.,
RA   Acharya K.R., Potter B.V.;
RT   "Crystal structure of human carbonic anhydrase II at 1.95 A resolution
RT   in complex with 667-coumate, a novel anti-cancer agent.";
RL   Biochem. J. 385:715-720(2005).
RN   [65]
RP   X-RAY CRYSTALLOGRAPHY (1.63 ANGSTROMS), MUTAGENESIS OF ASN-62; HIS-64
RP   AND ASN-67, AND BIOPHYSICOCHEMICAL PROPERTIES.
RX   PubMed=15667203; DOI=10.1021/bi0480279;
RA   Fisher Z., Hernandez Prada J.A., Tu C., Duda D., Yoshioka C., An H.,
RA   Govindasamy L., Silverman D.N., McKenna R.;
RT   "Structural and kinetic characterization of active-site histidine as a
RT   proton shuttle in catalysis by human carbonic anhydrase II.";
RL   Biochemistry 44:1097-1105(2005).
RN   [66]
RP   X-RAY CRYSTALLOGRAPHY (1.76 ANGSTROMS) IN COMPLEX WITH DUAL
RP   AROMATASE-STEROID SULFATASE INHIBITORS.
RX   PubMed=15865431; DOI=10.1021/bi047692e;
RA   Lloyd M.D., Thiyagarajan N., Ho Y.T., Woo L.W., Sutcliffe O.B.,
RA   Purohit A., Reed M.J., Acharya K.R., Potter B.V.;
RT   "First crystal structures of human carbonic anhydrase II in complex
RT   with dual aromatase-steroid sulfatase inhibitors.";
RL   Biochemistry 44:6858-6866(2005).
RN   [67]
RP   X-RAY CRYSTALLOGRAPHY (2.00 ANGSTROMS) IN COMPLEX WITH ACTIVATOR
RP   L-HISTIDINE, AND ENZYME REGULATION.
RX   PubMed=16214338; DOI=10.1016/j.bmcl.2005.08.069;
RA   Temperini C., Scozzafava A., Puccetti L., Supuran C.T.;
RT   "Carbonic anhydrase activators: X-ray crystal structure of the adduct
RT   of human isozyme II with L-histidine as a platform for the design of
RT   stronger activators.";
RL   Bioorg. Med. Chem. Lett. 15:5136-5141(2005).
RN   [68]
RP   X-RAY CRYSTALLOGRAPHY (2.00 ANGSTROMS) IN COMPLEX WITH INHIBITOR.
RX   PubMed=16134940; DOI=10.1021/jm050333c;
RA   Menchise V., De Simone G., Alterio V., Di Fiore A., Pedone C.,
RA   Scozzafava A., Supuran C.T.;
RT   "Carbonic anhydrase inhibitors: stacking with Phe131 determines active
RT   site binding region of inhibitors as exemplified by the X-ray crystal
RT   structure of a membrane-impermeant antitumor sulfonamide complexed
RT   with isozyme II.";
RL   J. Med. Chem. 48:5721-5727(2005).
RN   [69]
RP   X-RAY CRYSTALLOGRAPHY (1.70 ANGSTROMS), AND MUTAGENESIS OF HIS-64 AND
RP   THR-199.
RX   PubMed=16106378; DOI=10.1002/prot.20615;
RA   Bhatt D., Tu C., Fisher S.Z., Hernandez Prada J.A., McKenna R.,
RA   Silverman D.N.;
RT   "Proton transfer in a Thr200His mutant of human carbonic anhydrase
RT   II.";
RL   Proteins 61:239-245(2005).
RN   [70]
RP   X-RAY CRYSTALLOGRAPHY (1.50 ANGSTROMS).
RX   PubMed=16511248; DOI=10.1107/S1744309105038248;
RA   Budayova-Spano M., Fisher S.Z., Dauvergne M.T., Agbandje-McKenna M.,
RA   Silverman D.N., Myles D.A., McKenna R.;
RT   "Production and X-ray crystallographic analysis of fully deuterated
RT   human carbonic anhydrase II.";
RL   Acta Crystallogr. F 62:6-9(2006).
RN   [71]
RP   X-RAY CRYSTALLOGRAPHY (1.15 ANGSTROMS) IN COMPLEX WITH INHIBITORS.
RX   PubMed=16820676; DOI=10.1107/S1744309106020446;
RA   Fisher S.Z., Govindasamy L., Boyle N., Agbandje-McKenna M.,
RA   Silverman D.N., Blackburn G.M., McKenna R.;
RT   "X-ray crystallographic studies reveal that the incorporation of
RT   spacer groups in carbonic anhydrase inhibitors causes alternate
RT   binding modes.";
RL   Acta Crystallogr. F 62:618-622(2006).
RN   [72]
RP   X-RAY CRYSTALLOGRAPHY (1.46 ANGSTROMS) IN COMPLEX WITH INHIBITORS
RP   VALDECOXIB AND CELECOXIB, AND ENZYME REGULATION.
RX   PubMed=16290146; DOI=10.1016/j.bmcl.2005.09.040;
RA   Di Fiore A., Pedone C., D'Ambrosio K., Scozzafava A., De Simone G.,
RA   Supuran C.T.;
RT   "Carbonic anhydrase inhibitors: Valdecoxib binds to a different active
RT   site region of the human isoform II as compared to the structurally
RT   related cyclooxygenase II 'selective' inhibitor celecoxib.";
RL   Bioorg. Med. Chem. Lett. 16:437-442(2006).
RN   [73]
RP   X-RAY CRYSTALLOGRAPHY (2.00 ANGSTROMS) IN COMPLEX WITH N-HYDROXYUREA,
RP   AND ENZYME REGULATION.
RX   PubMed=16759856; DOI=10.1016/j.bmcl.2006.05.068;
RA   Temperini C., Innocenti A., Scozzafava A., Supuran C.T.;
RT   "N-hydroxyurea -- a versatile zinc binding function in the design of
RT   metalloenzyme inhibitors.";
RL   Bioorg. Med. Chem. Lett. 16:4316-4320(2006).
RN   [74]
RP   X-RAY CRYSTALLOGRAPHY (1.55 ANGSTROMS) IN COMPLEX WITH INHIBITORS.
RX   PubMed=17000110; DOI=10.1016/j.bmcl.2006.09.022;
RA   Menchise V., De Simone G., Di Fiore A., Scozzafava A., Supuran C.T.;
RT   "Carbonic anhydrase inhibitors: X-ray crystallographic studies for the
RT   binding of 5-amino-1,3,4-thiadiazole-2-sulfonamide and 5-(4-amino-3-
RT   chloro-5-fluorophenylsulfonamido)-1,3,4-thiadiazole-2-sulfonamide to
RT   human isoform II.";
RL   Bioorg. Med. Chem. Lett. 16:6204-6208(2006).
RN   [75]
RP   X-RAY CRYSTALLOGRAPHY (2.00 ANGSTROMS) IN COMPLEX WITH L- AND
RP   D-HISTIDINE, AND ENZYME REGULATION.
RX   PubMed=16807956; DOI=10.1002/chem.200600159;
RA   Temperini C., Scozzafava A., Vullo D., Supuran C.T.;
RT   "Carbonic anhydrase activators. Activation of isozymes I, II, IV, VA,
RT   VII, and XIV with l- and d-histidine and crystallographic analysis of
RT   their adducts with isoform II: engineering proton-transfer processes
RT   within the active site of an enzyme.";
RL   Chemistry 12:7057-7066(2006).
RN   [76]
RP   X-RAY CRYSTALLOGRAPHY (0.99 ANGSTROMS) IN COMPLEX WITH TWO-PRONG
RP   INHIBITORS.
RX   PubMed=16506782; DOI=10.1021/ja057257n;
RA   Jude K.M., Banerjee A.L., Haldar M.K., Manokaran S., Roy B.,
RA   Mallik S., Srivastava D.K., Christianson D.W.;
RT   "Ultrahigh resolution crystal structures of human carbonic anhydrases
RT   I and II complexed with 'two-prong' inhibitors reveal the molecular
RT   basis of high affinity.";
RL   J. Am. Chem. Soc. 128:3011-3018(2006).
RN   [77]
RP   X-RAY CRYSTALLOGRAPHY (1.71 ANGSTROMS) IN COMPLEX WITH INHIBITOR.
RX   PubMed=16787097; DOI=10.1021/ja061574s;
RA   Alterio V., Vitale R.M., Monti S.M., Pedone C., Scozzafava A.,
RA   Cecchi A., De Simone G., Supuran C.T.;
RT   "Carbonic anhydrase inhibitors: X-ray and molecular modeling study for
RT   the interaction of a fluorescent antitumor sulfonamide with isozyme II
RT   and IX.";
RL   J. Am. Chem. Soc. 128:8329-8335(2006).
RN   [78]
RP   X-RAY CRYSTALLOGRAPHY (1.60 ANGSTROMS) IN COMPLEX WITH L- AND
RP   D-PHENYLALANINE, AND ENZYME REGULATION.
RX   PubMed=16686544; DOI=10.1021/jm0603320;
RA   Temperini C., Scozzafava A., Vullo D., Supuran C.T.;
RT   "Carbonic anhydrase activators. Activation of isoforms I, II, IV, VA,
RT   VII, and XIV with L- and D-phenylalanine and crystallographic analysis
RT   of their adducts with isozyme II: stereospecific recognition within
RT   the active site of an enzyme and its consequences for the drug
RT   design.";
RL   J. Med. Chem. 49:3019-3027(2006).
RN   [79]
RP   X-RAY CRYSTALLOGRAPHY (1.80 ANGSTROMS) IN COMPLEX WITH INHIBITOR.
RX   PubMed=16942027; DOI=10.1021/jm060531j;
RA   De Simone G., Vitale R.M., Di Fiore A., Pedone C., Scozzafava A.,
RA   Montero J.-L., Winum J.-Y., Supuran C.T.;
RT   "Carbonic anhydrase inhibitors: Hypoxia-activatable sulfonamides
RT   incorporating disulfide bonds that target the tumor-associated isoform
RT   IX.";
RL   J. Med. Chem. 49:5544-5551(2006).
RN   [80]
RP   X-RAY CRYSTALLOGRAPHY (1.90 ANGSTROMS) IN COMPLEX WITH INHIBITOR.
RX   PubMed=17125255; DOI=10.1021/jm060807n;
RA   Winum J.Y., Temperini C., El Cheikh K., Innocenti A., Vullo D.,
RA   Ciattini S., Montero J.-L., Scozzafava A., Supuran C.T.;
RT   "Carbonic anhydrase inhibitors: clash with Ala65 as a means for
RT   designing inhibitors with low affinity for the ubiquitous isozyme II,
RT   exemplified by the crystal structure of the topiramate sulfamide
RT   analogue.";
RL   J. Med. Chem. 49:7024-7031(2006).
RN   [81]
RP   X-RAY CRYSTALLOGRAPHY (1.46 ANGSTROMS) IN COMPLEX WITH INHIBITORS.
RX   PubMed=17181151; DOI=10.1021/jm060705x;
RA   Leese M.P., Leblond B., Smith A., Newman S.P., Di Fiore A.,
RA   De Simone G., Supuran C.T., Purohit A., Reed M.J., Potter B.V.;
RT   "2-substituted estradiol bis-sulfamates, multitargeted antitumor
RT   agents: synthesis, in vitro SAR, protein crystallography, and in vivo
RT   activity.";
RL   J. Med. Chem. 49:7683-7696(2006).
RN   [82]
RP   X-RAY CRYSTALLOGRAPHY (1.70 ANGSTROMS) IN COMPLEX WITH SACCHARIN, AND
RP   ENZYME REGULATION.
RX   PubMed=17705204; DOI=10.1002/anie.200701189;
RA   Koehler K., Hillebrecht A., Schulze Wischeler J., Innocenti A.,
RA   Heine A., Supuran C.T., Klebe G.;
RT   "Saccharin inhibits carbonic anhydrases: possible explanation for its
RT   unpleasant metallic aftertaste.";
RL   Angew. Chem. Int. Ed. Engl. 46:7697-7699(2007).
RN   [83]
RP   X-RAY CRYSTALLOGRAPHY (1.05 ANGSTROMS).
RX   PubMed=17319692; DOI=10.1021/bi062066y;
RA   Fisher S.Z., Maupin C.M., Budayova-Spano M., Govindasamy L., Tu C.,
RA   Agbandje-McKenna M., Silverman D.N., Voth G.A., McKenna R.;
RT   "Atomic crystal and molecular dynamics simulation structures of human
RT   carbonic anhydrase II: insights into the proton transfer mechanism.";
RL   Biochemistry 46:2930-2937(2007).
RN   [84]
RP   X-RAY CRYSTALLOGRAPHY (1.15 ANGSTROMS), MUTAGENESIS OF TYR-7; ASN-62
RP   AND ASN-67, AND BIOPHYSICOCHEMICAL PROPERTIES.
RX   PubMed=17330962; DOI=10.1021/bi602620k;
RA   Fisher S.Z., Tu C., Bhatt D., Govindasamy L., Agbandje-McKenna M.,
RA   McKenna R., Silverman D.N.;
RT   "Speeding up proton transfer in a fast enzyme: kinetic and
RT   crystallographic studies on the effect of hydrophobic amino acid
RT   substitutions in the active site of human carbonic anhydrase II.";
RL   Biochemistry 46:3803-3813(2007).
RN   [85]
RP   X-RAY CRYSTALLOGRAPHY (1.90 ANGSTROMS) IN COMPLEX WITH ACTIVATOR
RP   L-ADRENALINE, AND ENZYME REGULATION.
RX   PubMed=17127057; DOI=10.1016/j.bmcl.2006.11.027;
RA   Temperini C., Innocenti A., Scozzafava A., Mastrolorenzo A.,
RA   Supuran C.T.;
RT   "Carbonic anhydrase activators: L-Adrenaline plugs the active site
RT   entrance of isozyme II, activating better isoforms I, IV, VA, VII, and
RT   XIV.";
RL   Bioorg. Med. Chem. Lett. 17:628-635(2007).
RN   [86]
RP   X-RAY CRYSTALLOGRAPHY (1.55 ANGSTROMS) IN COMPLEX WITH INHIBITOR.
RX   PubMed=17251017; DOI=10.1016/j.bmcl.2006.12.099;
RA   Di Fiore A., Scozzafava A., Winum J.-Y., Montero J.-L., Pedone C.,
RA   Supuran C.T., De Simone G.;
RT   "Carbonic anhydrase inhibitors: binding of an antiglaucoma glycosyl-
RT   sulfanilamide derivative to human isoform II and its consequences for
RT   the drug design of enzyme inhibitors incorporating sugar moieties.";
RL   Bioorg. Med. Chem. Lett. 17:1726-1731(2007).
RN   [87]
RP   X-RAY CRYSTALLOGRAPHY (2.10 ANGSTROMS) IN COMPLEX WITH INHIBITOR
RP   N-HYDROXYSULFAMIDE.
RX   PubMed=17346964; DOI=10.1016/j.bmcl.2007.02.068;
RA   Temperini C., Winum J.Y., Montero J.L., Scozzafava A., Supuran C.T.;
RT   "Carbonic anhydrase inhibitors: the X-ray crystal structure of the
RT   adduct of N-hydroxysulfamide with isozyme II explains why this new
RT   zinc binding function is effective in the design of potent
RT   inhibitors.";
RL   Bioorg. Med. Chem. Lett. 17:2795-2801(2007).
RN   [88]
RP   X-RAY CRYSTALLOGRAPHY (1.60 ANGSTROMS) IN COMPLEX WITH INHIBITORS, AND
RP   ENZYME REGULATION.
RX   PubMed=17540563; DOI=10.1016/j.bmcl.2007.05.045;
RA   Alterio V., De Simone G., Monti S.M., Scozzafava A., Supuran C.T.;
RT   "Carbonic anhydrase inhibitors: inhibition of human, bacterial, and
RT   archaeal isozymes with benzene-1,3-disulfonamides -- solution and
RT   crystallographic studies.";
RL   Bioorg. Med. Chem. Lett. 17:4201-4207(2007).
RN   [89]
RP   X-RAY CRYSTALLOGRAPHY (1.90 ANGSTROMS) IN COMPLEX WITH INHIBITORS, AND
RP   ENZYME REGULATION.
RX   PubMed=17588751; DOI=10.1016/j.bmcl.2007.06.044;
RA   Temperini C., Innocenti A., Mastrolorenzo A., Scozzafava A.,
RA   Supuran C.T.;
RT   "Carbonic anhydrase inhibitors. Interaction of the antiepileptic drug
RT   sulthiame with twelve mammalian isoforms: kinetic and X-ray
RT   crystallographic studies.";
RL   Bioorg. Med. Chem. Lett. 17:4866-4872(2007).
RN   [90]
RP   X-RAY CRYSTALLOGRAPHY (1.80 ANGSTROMS) IN COMPLEX WITH
RP   4-METHYLIMIDAZOLE, AND MUTAGENESIS OF TRP-5 AND HIS-64.
RX   PubMed=17071654; DOI=10.1529/biophysj.106.093203;
RA   Bhatt D., Fisher S.Z., Tu C., McKenna R., Silverman D.N.;
RT   "Location of binding sites in small molecule rescue of human carbonic
RT   anhydrase II.";
RL   Biophys. J. 92:562-570(2007).
RN   [91]
RP   X-RAY CRYSTALLOGRAPHY (1.01 ANGSTROMS) IN COMPLEX WITH INHIBITORS.
RX   PubMed=17407288; DOI=10.1021/ja068359w;
RA   Srivastava D.K., Jude K.M., Banerjee A.L., Haldar M., Manokaran S.,
RA   Kooren J., Mallik S., Christianson D.W.;
RT   "Structural analysis of charge discrimination in the binding of
RT   inhibitors to human carbonic anhydrases I and II.";
RL   J. Am. Chem. Soc. 129:5528-5537(2007).
RN   [92]
RP   X-RAY CRYSTALLOGRAPHY (1.60 ANGSTROMS) IN COMPLEX WITH INHIBITOR
RP   THIOXOLONE, AND ENZYME REGULATION.
RX   PubMed=18266323; DOI=10.1021/bi702385k;
RA   Barrese A.A. III, Genis C., Fisher S.Z., Orwenyo J.N., Kumara M.T.,
RA   Dutta S.K., Phillips E., Kiddle J.J., Tu C., Silverman D.N.,
RA   Govindasamy L., Agbandje-McKenna M., McKenna R., Tripp B.C.;
RT   "Inhibition of carbonic anhydrase II by thioxolone: a mechanistic and
RT   structural study.";
RL   Biochemistry 47:3174-3184(2008).
RN   [93]
RP   X-RAY CRYSTALLOGRAPHY (1.60 ANGSTROMS) OF MUTANTS, MUTAGENESIS OF
RP   ASN-62, AND BIOPHYSICOCHEMICAL PROPERTIES.
RX   PubMed=18942852; DOI=10.1021/bi801473w;
RA   Zheng J., Avvaru B.S., Tu C., McKenna R., Silverman D.N.;
RT   "Role of hydrophilic residues in proton transfer during catalysis by
RT   human carbonic anhydrase II.";
RL   Biochemistry 47:12028-12036(2008).
RN   [94]
RP   X-RAY CRYSTALLOGRAPHY (1.89 ANGSTROMS) IN COMPLEX WITH INHIBITORS, AND
RP   ENZYME REGULATION.
RX   PubMed=18024029; DOI=10.1016/j.bmcl.2007.10.110;
RA   Guezel O., Temperini C., Innocenti A., Scozzafava A., Salman A.,
RA   Supuran C.T.;
RT   "Carbonic anhydrase inhibitors. Interaction of 2-(hydrazinocarbonyl)-
RT   3-phenyl-1H-indole-5-sulfonamide with 12 mammalian isoforms: kinetic
RT   and X-ray crystallographic studies.";
RL   Bioorg. Med. Chem. Lett. 18:152-158(2008).
RN   [95]
RP   X-RAY CRYSTALLOGRAPHY (1.90 ANGSTROMS) IN COMPLEX WITH INHIBITORS, AND
RP   ENZYME REGULATION.
RX   PubMed=18162396; DOI=10.1016/j.bmcl.2007.12.022;
RA   Temperini C., Cecchi A., Boyle N.A., Scozzafava A., Cabeza J.E.,
RA   Wentworth P. Jr., Blackburn G.M., Supuran C.T.;
RT   "Carbonic anhydrase inhibitors. Interaction of 2-N,N-dimethylamino-
RT   1,3,4-thiadiazole-5-methanesulfonamide with 12 mammalian isoforms:
RT   kinetic and X-ray crystallographic studies.";
RL   Bioorg. Med. Chem. Lett. 18:999-1005(2008).
RN   [96]
RP   X-RAY CRYSTALLOGRAPHY (2.10 ANGSTROMS) IN COMPLEX WITH INHIBITORS, AND
RP   ENZYME REGULATION.
RX   PubMed=18374572; DOI=10.1016/j.bmcl.2008.03.051;
RA   Temperini C., Cecchi A., Scozzafava A., Supuran C.T.;
RT   "Carbonic anhydrase inhibitors. Interaction of indapamide and related
RT   diuretics with 12 mammalian isozymes and X-ray crystallographic
RT   studies for the indapamide-isozyme II adduct.";
RL   Bioorg. Med. Chem. Lett. 18:2567-2573(2008).
RN   [97]
RP   X-RAY CRYSTALLOGRAPHY (1.80 ANGSTROMS) IN COMPLEX WITH INHIBITORS.
RX   PubMed=18359629; DOI=10.1016/j.bmcl.2008.03.023;
RA   Di Fiore A., Pedone C., Antel J., Waldeck H., Witte A., Wurl M.,
RA   Scozzafava A., Supuran C.T., De Simone G.;
RT   "Carbonic anhydrase inhibitors: the X-ray crystal structure of
RT   ethoxzolamide complexed to human isoform II reveals the importance of
RT   thr200 and gln92 for obtaining tight-binding inhibitors.";
RL   Bioorg. Med. Chem. Lett. 18:2669-2674(2008).
RN   [98]
RP   X-RAY CRYSTALLOGRAPHY (1.90 ANGSTROMS) IN COMPLEX WITH INHIBITORS, AND
RP   ENZYME REGULATION.
RX   PubMed=18640037; DOI=10.1016/j.bmcl.2008.06.105;
RA   Temperini C., Innocenti A., Scozzafava A., Supuran C.T.;
RT   "Carbonic anhydrase inhibitors. Interaction of the antitumor sulfamate
RT   EMD 486019 with twelve mammalian carbonic anhydrase isoforms: Kinetic
RT   and X-ray crystallographic studies.";
RL   Bioorg. Med. Chem. Lett. 18:4282-4286(2008).
RN   [99]
RP   X-RAY CRYSTALLOGRAPHY (1.40 ANGSTROMS) IN COMPLEX WITH INHIBITORS
RP   INDANESULFONAMIDES.
RX   PubMed=18161740; DOI=10.1002/cmdc.200700274;
RA   D'Ambrosio K., Masereel B., Thiry A., Scozzafava A., Supuran C.T.,
RA   De Simone G.;
RT   "Carbonic anhydrase inhibitors: binding of indanesulfonamides to the
RT   human isoform II.";
RL   ChemMedChem 3:473-477(2008).
RN   [100]
RP   X-RAY CRYSTALLOGRAPHY (1.70 ANGSTROMS) IN COMPLEX WITH
RP   (129)XE-CRYPTOPHANE BIOSENSOR.
RX   PubMed=18461940; DOI=10.1021/ja802214x;
RA   Aaron J.A., Chambers J.M., Jude K.M., Di Costanzo L., Dmochowski I.J.,
RA   Christianson D.W.;
RT   "Structure of a (129)Xe-cryptophane biosensor complexed with human
RT   carbonic anhydrase II.";
RL   J. Am. Chem. Soc. 130:6942-6943(2008).
RN   [101]
RP   X-RAY CRYSTALLOGRAPHY (1.10 ANGSTROMS) IN COMPLEX WITH CO2.
RX   PubMed=18768466; DOI=10.1074/jbc.M805353200;
RA   Domsic J.F., Avvaru B.S., Kim C.U., Gruner S.M., Agbandje-McKenna M.,
RA   Silverman D.N., McKenna R.;
RT   "Entrapment of carbon dioxide in the active site of carbonic anhydrase
RT   II.";
RL   J. Biol. Chem. 283:30766-30771(2008).
RN   [102]
RP   X-RAY CRYSTALLOGRAPHY (1.85 ANGSTROMS) IN COMPLEX WITH INHIBITORS.
RX   PubMed=18260615; DOI=10.1021/jm701319c;
RA   Leese M.P., Jourdan F.L., Gaukroger K., Mahon M.F., Newman S.P.,
RA   Foster P.A., Stengel C., Regis-Lydi S., Ferrandis E., Di Fiore A.,
RA   De Simone G., Supuran C.T., Purohit A., Reed M.J., Potter B.V.;
RT   "Structure-activity relationships of C-17 cyano-substituted
RT   estratrienes as anticancer agents.";
RL   J. Med. Chem. 51:1295-1308(2008).
RN   [103]
RP   X-RAY CRYSTALLOGRAPHY (1.45 ANGSTROMS) IN COMPLEX WITH INHIBITORS, AND
RP   ENZYME REGULATION.
RX   PubMed=18481843; DOI=10.1021/jm800121c;
RA   D'Ambrosio K., Vitale R.-M., Dogne J.-M., Masereel B., Innocenti A.,
RA   Scozzafava A., De Simone G., Supuran C.T.;
RT   "Carbonic anhydrase inhibitors: bioreductive nitro-containing
RT   sulfonamides with selectivity for targeting the tumor associated
RT   isoforms IX and XII.";
RL   J. Med. Chem. 51:3230-3237(2008).
RN   [104]
RP   X-RAY CRYSTALLOGRAPHY (1.70 ANGSTROMS) IN COMPLEX WITH INHIBITORS.
RX   PubMed=18723489; DOI=10.1158/1535-7163.MCT-08-0195;
RA   Woo L.W.L., Fischer D.S., Sharland C.M., Trusselle M., Foster P.A.,
RA   Chander S.K., Di Fiore A., Supuran C.T., De Simone G., Purohit A.,
RA   Reed M.J., Potter B.V.L.;
RT   "Anticancer steroid sulfatase inhibitors: synthesis of a potent
RT   fluorinated second-generation agent, in vitro and in vivo activities,
RT   molecular modeling, and protein crystallography.";
RL   Mol. Cancer Ther. 7:2435-2444(2008).
RN   [105]
RP   X-RAY CRYSTALLOGRAPHY (1.48 ANGSTROMS) IN COMPLEX WITH INHIBITORS,
RP   ENZYME REGULATION, AND MUTAGENESIS OF ALA-65 AND ASN-67.
RX   PubMed=19170619; DOI=10.1021/bi802035f;
RA   Genis C., Sippel K.H., Case N., Cao W., Avvaru B.S., Tartaglia L.J.,
RA   Govindasamy L., Tu C., Agbandje-McKenna M., Silverman D.N.,
RA   Rosser C.J., McKenna R.;
RT   "Design of a carbonic anhydrase IX active-site mimic to screen
RT   inhibitors for possible anticancer properties.";
RL   Biochemistry 48:1322-1331(2009).
RN   [106]
RP   X-RAY CRYSTALLOGRAPHY (1.26 ANGSTROMS) FREE AND IN COMPLEX WITH ZINC
RP   ION, AND COFACTOR.
RX   PubMed=19583303; DOI=10.1021/bi9007512;
RA   Avvaru B.S., Busby S.A., Chalmers M.J., Griffin P.R.,
RA   Venkatakrishnan B., Agbandje-McKenna M., Silverman D.N., McKenna R.;
RT   "Apo-human carbonic anhydrase II revisited: implications of the loss
RT   of a metal in protein structure, stability, and solvent network.";
RL   Biochemistry 48:7365-7372(2009).
RN   [107]
RP   X-RAY CRYSTALLOGRAPHY (1.81 ANGSTROMS) OF 1-260 IN COMPLEX WITH
RP   INHIBITOR THIABENDAZOLE-5-SULFONAMIDE, AND ENZYME REGULATION.
RX   PubMed=19186056; DOI=10.1016/j.bmcl.2009.01.038;
RA   Crocetti L., Maresca A., Temperini C., Hall R.A., Scozzafava A.,
RA   Muehlschlegel F.A., Supuran C.T.;
RT   "A thiabendazole sulfonamide shows potent inhibitory activity against
RT   mammalian and nematode alpha-carbonic anhydrases.";
RL   Bioorg. Med. Chem. Lett. 19:1371-1375(2009).
RN   [108]
RP   X-RAY CRYSTALLOGRAPHY (2.00 ANGSTROMS) OF 1-260 IN COMPLEX WITH
RP   COUMARIN INHIBITORS, AND ENZYME REGULATION.
RX   PubMed=19206230; DOI=10.1021/ja809683v;
RA   Maresca A., Temperini C., Vu H., Pham N.B., Poulsen S.-A.,
RA   Scozzafava A., Quinn R.J., Supuran C.T.;
RT   "Non-zinc mediated inhibition of carbonic anhydrases: coumarins are a
RT   new class of suicide inhibitors.";
RL   J. Am. Chem. Soc. 131:3057-3062(2009).
RN   [109]
RP   X-RAY CRYSTALLOGRAPHY (1.90 ANGSTROMS) IN COMPLEX WITH INHIBITORS.
RX   PubMed=19115843; DOI=10.1021/jm801386n;
RA   Temperini C., Cecchi A., Scozzafava A., Supuran C.T.;
RT   "Carbonic anhydrase inhibitors. Comparison of chlorthalidone and
RT   indapamide X-ray crystal structures in adducts with isozyme II: when
RT   three water molecules and the keto-enol tautomerism make the
RT   difference.";
RL   J. Med. Chem. 52:322-328(2009).
RN   [110]
RP   X-RAY CRYSTALLOGRAPHY (1.41 ANGSTROMS) IN COMPLEX WITH INHIBITORS.
RX   PubMed=19731956; DOI=10.1021/jm900641r;
RA   Vitale R.M., Alterio V., Innocenti A., Winum J.-Y., Monti S.M.,
RA   De Simone G., Supuran C.T.;
RT   "Carbonic anhydrase inhibitors. Comparison of aliphatic sulfamate/bis-
RT   sulfamate adducts with isozymes II and IX as a platform for designing
RT   tight-binding, more isoform-selective inhibitors.";
RL   J. Med. Chem. 52:5990-5998(2009).
RN   [111]
RP   X-RAY CRYSTALLOGRAPHY (1.80 ANGSTROMS) OF 1-260 IN COMPLEX WITH
RP   INHIBITORS.
RX   PubMed=19827837; DOI=10.1021/jm900914e;
RA   Lopez M., Paul B., Hofmann A., Morizzi J., Wu Q.K., Charman S.A.,
RA   Innocenti A., Vullo D., Supuran C.T., Poulsen S.-A.;
RT   "S-glycosyl primary sulfonamides--a new structural class for selective
RT   inhibition of cancer-associated carbonic anhydrases.";
RL   J. Med. Chem. 52:6421-6432(2009).
RN   [112]
RP   X-RAY CRYSTALLOGRAPHY (1.85 ANGSTROMS) OF 1-260 IN COMPLEX WITH
RP   INHIBITORS, AND ENZYME REGULATION.
RX   PubMed=19778001; DOI=10.1021/jp906593c;
RA   Ciani L., Cecchi A., Temperini C., Supuran C.T., Ristori S.;
RT   "Dissecting the inhibition mechanism of cytosolic versus transmembrane
RT   carbonic anhydrases by ESR.";
RL   J. Phys. Chem. B 113:13998-14005(2009).
RN   [113]
RP   X-RAY CRYSTALLOGRAPHY (1.56 ANGSTROMS) IN COMPLEX WITH SUBSTRATES, AND
RP   ENZYME REGULATION.
RX   PubMed=19520834; DOI=10.1073/pnas.0904184106;
RA   Sjoeblom B., Polentarutti M., Djinovic-Carugo K.;
RT   "Structural study of X-ray induced activation of carbonic anhydrase.";
RL   Proc. Natl. Acad. Sci. U.S.A. 106:10609-10613(2009).
RN   [114]
RP   VARIANT JOGJAKARTA GLU-18.
RX   PubMed=6817747; DOI=10.1007/BF00484072;
RA   Jones G.L., Sofro A.S.M., Shaw D.C.;
RT   "Chemical and enzymological characterization of an Indonesian variant
RT   of human erythrocyte carbonic anhydrase II, CAII Jogjakarta (17 Lys
RT   leads to Glu).";
RL   Biochem. Genet. 20:979-1000(1982).
RN   [115]
RP   VARIANT MELBOURNE HIS-236.
RX   PubMed=6407977; DOI=10.1007/BF00274768;
RA   Jones G.L., Shaw D.C.;
RT   "A chemical and enzymological comparison of the common major human
RT   erythrocyte carbonic anhydrase II, its minor component, and a new
RT   genetic variant, CA II Melbourne (237 Pro leads to His).";
RL   Hum. Genet. 63:392-399(1983).
RN   [116]
RP   VARIANT OPTB3 TYR-107.
RX   PubMed=1928091;
RA   Venta P.J., Welty R.J., Johnson T.M., Sly W.S., Tashian R.E.;
RT   "Carbonic anhydrase II deficiency syndrome in a Belgian family is
RT   caused by a point mutation at an invariant histidine residue (107
RT   His-->Tyr): complete structure of the normal human CA II gene.";
RL   Am. J. Hum. Genet. 49:1082-1090(1991).
RN   [117]
RP   VARIANT OPTB3 TYR-107.
RX   PubMed=1542674; DOI=10.1073/pnas.89.5.1804;
RA   Roth D.E., Venta P.J., Tashian R.E., Sly W.S.;
RT   "Molecular basis of human carbonic anhydrase II deficiency.";
RL   Proc. Natl. Acad. Sci. U.S.A. 89:1804-1808(1992).
RN   [118]
RP   VARIANT OPTB3 TYR-107.
RX   PubMed=8834238; DOI=10.1007/BF02267062;
RA   Soda H., Yukizane S., Yoshida I., Koga Y., Aramaki S., Kato H.;
RT   "A point mutation in exon 3 (His 107-->Tyr) in two unrelated Japanese
RT   patients with carbonic anhydrase II deficiency with central nervous
RT   system involvement.";
RL   Hum. Genet. 97:435-437(1996).
RN   [119]
RP   VARIANT OPTB3 PRO-92.
RX   PubMed=9143915;
RX   DOI=10.1002/(SICI)1098-1004(1997)9:5<383::AID-HUMU1>3.3.CO;2-K;
RA   Hu P.Y., Lim E.J., Ciccolella J., Strisciuglio P., Sly W.S.;
RT   "Seven novel mutations in carbonic anhydrase II deficiency syndrome
RT   identified by SSCP and direct sequencing analysis.";
RL   Hum. Mutat. 9:383-387(1997).
RN   [120]
RP   VARIANTS OPTB3 PRO-92; TYR-94; TYR-107 AND ARG-144, AND
RP   CHARACTERIZATION OF VARIANTS TYR-94 AND ARG-144.
RX   PubMed=15300855; DOI=10.1002/humu.9266;
RA   Shah G.N., Bonapace G., Hu P.Y., Strisciuglio P., Sly W.S.;
RT   "Carbonic anhydrase II deficiency syndrome (osteopetrosis with renal
RT   tubular acidosis and brain calcification): novel mutations in CA2
RT   identified by direct sequencing expand the opportunity for genotype-
RT   phenotype correlation.";
RL   Hum. Mutat. 24:272-272(2004).
CC   -!- FUNCTION: Essential for bone resorption and osteoclast
CC       differentiation (By similarity). Reversible hydration of carbon
CC       dioxide. Can hydrate cyanamide to urea. Involved in the regulation
CC       of fluid secretion into the anterior chamber of the eye.
CC       Contributes to intracellular pH regulation in the duodenal upper
CC       villous epithelium during proton-coupled peptide absorption.
CC       Stimulates the chloride-bicarbonate exchange activity of SLC26A6.
CC       {ECO:0000250, ECO:0000269|PubMed:10550681,
CC       ECO:0000269|PubMed:11831900, ECO:0000269|PubMed:15990874}.
CC   -!- CATALYTIC ACTIVITY: H(2)CO(3) = CO(2) + H(2)O.
CC   -!- COFACTOR:
CC       Name=Zn(2+); Xref=ChEBI:CHEBI:29105;
CC         Evidence={ECO:0000269|PubMed:11076507,
CC         ECO:0000269|PubMed:12499545, ECO:0000269|PubMed:1336460,
CC         ECO:0000269|PubMed:1433293, ECO:0000269|PubMed:1909891,
CC         ECO:0000269|PubMed:19583303, ECO:0000269|PubMed:3151019,
CC         ECO:0000269|PubMed:3151020, ECO:0000269|PubMed:7761440,
CC         ECO:0000269|PubMed:7803386, ECO:0000269|PubMed:7901850,
CC         ECO:0000269|PubMed:8218160, ECO:0000269|PubMed:8262987,
CC         ECO:0000269|PubMed:8331673, ECO:0000269|PubMed:8399159,
CC         ECO:0000269|PubMed:8431430, ECO:0000269|PubMed:8451242,
CC         ECO:0000269|PubMed:8482389, ECO:0000269|PubMed:8639494,
CC         ECO:0000269|PubMed:8987974, ECO:0000269|PubMed:9398308,
CC         ECO:0000269|PubMed:9865942};
CC       Name=Co(2+); Xref=ChEBI:CHEBI:48828;
CC         Evidence={ECO:0000269|PubMed:19583303};
CC       Note=Zinc. Can also use cobalt(II) with lower efficiency, but not
CC       copper(II), nickel(II) and manganese(II).
CC       {ECO:0000269|PubMed:19583303};
CC   -!- ENZYME REGULATION: Activated by X-ray, histamine, L-adrenaline, L-
CC       and D-phenylalanine, L- and D-histidine, L-His-OMe and beta-Ala-
CC       His (carnosine). Competitively inhibited by saccharin, thioxolone,
CC       coumarins, 667-coumate, celecoxib (Celebrex), valdecoxib (Bextra),
CC       SC-125, SC-560, diclofenac, acetate, azide, bromide, sulfonamide
CC       derivatives such as acetazolamide (AZA), methazolamide (MZA),
CC       ethoxzolamide (EZA), dichlorophenamide (DCP), brinzolamide,
CC       dansylamide, thiabendazole-5-sulfonamide, trifluoromethane
CC       sulfonamide and N-hydroxysulfamide, fructose-based sugar sulfamate
CC       RWJ-37497, and Foscarnet (phosphonoformate trisodium salt).
CC       Repressed strongly by hydrogen sulfide(HS) and weakly by nitrate
CC       (NO(3)). Esterase activity weakly reduced by cyanamide. N-
CC       hydroxyurea interfers with zinc binding and inhibit activity.
CC       {ECO:0000269|PubMed:11802772, ECO:0000269|PubMed:1336460,
CC       ECO:0000269|PubMed:14736236, ECO:0000269|PubMed:16214338,
CC       ECO:0000269|PubMed:16290146, ECO:0000269|PubMed:16686544,
CC       ECO:0000269|PubMed:16759856, ECO:0000269|PubMed:16807956,
CC       ECO:0000269|PubMed:17127057, ECO:0000269|PubMed:17314045,
CC       ECO:0000269|PubMed:17540563, ECO:0000269|PubMed:17588751,
CC       ECO:0000269|PubMed:17705204, ECO:0000269|PubMed:18024029,
CC       ECO:0000269|PubMed:18162396, ECO:0000269|PubMed:18266323,
CC       ECO:0000269|PubMed:18374572, ECO:0000269|PubMed:18481843,
CC       ECO:0000269|PubMed:18618712, ECO:0000269|PubMed:18640037,
CC       ECO:0000269|PubMed:1910042, ECO:0000269|PubMed:19170619,
CC       ECO:0000269|PubMed:19186056, ECO:0000269|PubMed:19206230,
CC       ECO:0000269|PubMed:19520834, ECO:0000269|PubMed:19778001,
CC       ECO:0000269|PubMed:9265618}.
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       Absorption:
CC         Abs(max)=~550 nm {ECO:0000269|PubMed:10550681,
CC         ECO:0000269|PubMed:15667203, ECO:0000269|PubMed:17330962,
CC         ECO:0000269|PubMed:18618712, ECO:0000269|PubMed:18942852,
CC         ECO:0000269|PubMed:1909891, ECO:0000269|PubMed:1910042,
CC         ECO:0000269|PubMed:7761440, ECO:0000269|PubMed:8262987,
CC         ECO:0000269|PubMed:9398308};
CC         Note=At pH 7.0. Shows a second maximum at 618 nm.;
CC       Kinetic parameters:
CC         KM=10 mM for CO(2) {ECO:0000269|PubMed:10550681,
CC         ECO:0000269|PubMed:15667203, ECO:0000269|PubMed:17330962,
CC         ECO:0000269|PubMed:18618712, ECO:0000269|PubMed:18942852,
CC         ECO:0000269|PubMed:1909891, ECO:0000269|PubMed:1910042,
CC         ECO:0000269|PubMed:7761440, ECO:0000269|PubMed:8262987,
CC         ECO:0000269|PubMed:9398308};
CC         KM=82 mM for H(2)CO(3) {ECO:0000269|PubMed:10550681,
CC         ECO:0000269|PubMed:15667203, ECO:0000269|PubMed:17330962,
CC         ECO:0000269|PubMed:18618712, ECO:0000269|PubMed:18942852,
CC         ECO:0000269|PubMed:1909891, ECO:0000269|PubMed:1910042,
CC         ECO:0000269|PubMed:7761440, ECO:0000269|PubMed:8262987,
CC         ECO:0000269|PubMed:9398308};
CC         KM=3 mM for 4-nitrophenyl acetate {ECO:0000269|PubMed:10550681,
CC         ECO:0000269|PubMed:15667203, ECO:0000269|PubMed:17330962,
CC         ECO:0000269|PubMed:18618712, ECO:0000269|PubMed:18942852,
CC         ECO:0000269|PubMed:1909891, ECO:0000269|PubMed:1910042,
CC         ECO:0000269|PubMed:7761440, ECO:0000269|PubMed:8262987,
CC         ECO:0000269|PubMed:9398308};
CC       pH dependence:
CC         Optimum pH is 6-8. {ECO:0000269|PubMed:10550681,
CC         ECO:0000269|PubMed:15667203, ECO:0000269|PubMed:17330962,
CC         ECO:0000269|PubMed:18618712, ECO:0000269|PubMed:18942852,
CC         ECO:0000269|PubMed:1909891, ECO:0000269|PubMed:1910042,
CC         ECO:0000269|PubMed:7761440, ECO:0000269|PubMed:8262987,
CC         ECO:0000269|PubMed:9398308};
CC   -!- SUBUNIT: Interacts with SLC4A4. Interaction with SLC4A7 regulates
CC       SLC4A7 transporter activity. Interacts with SLC26A6 isoform 4 (via
CC       C-terminus cytoplasmic domain). {ECO:0000269|PubMed:10550681,
CC       ECO:0000269|PubMed:11015219, ECO:0000269|PubMed:11076507,
CC       ECO:0000269|PubMed:11327835, ECO:0000269|PubMed:11572683,
CC       ECO:0000269|PubMed:11802772, ECO:0000269|PubMed:11818565,
CC       ECO:0000269|PubMed:11831900, ECO:0000269|PubMed:12056894,
CC       ECO:0000269|PubMed:12166932, ECO:0000269|PubMed:12499545,
CC       ECO:0000269|PubMed:1336460, ECO:0000269|PubMed:1433293,
CC       ECO:0000269|PubMed:14567693, ECO:0000269|PubMed:14736236,
CC       ECO:0000269|PubMed:14736710, ECO:0000269|PubMed:1474587,
CC       ECO:0000269|PubMed:15218065, ECO:0000269|PubMed:15299481,
CC       ECO:0000269|PubMed:15299482, ECO:0000269|PubMed:15453828,
CC       ECO:0000269|PubMed:15865431, ECO:0000269|PubMed:15990874,
CC       ECO:0000269|PubMed:16134940, ECO:0000269|PubMed:16214338,
CC       ECO:0000269|PubMed:16290146, ECO:0000269|PubMed:16506782,
CC       ECO:0000269|PubMed:16686544, ECO:0000269|PubMed:16759856,
CC       ECO:0000269|PubMed:16787097, ECO:0000269|PubMed:16807956,
CC       ECO:0000269|PubMed:16820676, ECO:0000269|PubMed:16942027,
CC       ECO:0000269|PubMed:17000110, ECO:0000269|PubMed:17071654,
CC       ECO:0000269|PubMed:17125255, ECO:0000269|PubMed:17127057,
CC       ECO:0000269|PubMed:17181151, ECO:0000269|PubMed:17251017,
CC       ECO:0000269|PubMed:17346964, ECO:0000269|PubMed:17407288,
CC       ECO:0000269|PubMed:17540563, ECO:0000269|PubMed:17588751,
CC       ECO:0000269|PubMed:17705204, ECO:0000269|PubMed:18024029,
CC       ECO:0000269|PubMed:18161740, ECO:0000269|PubMed:18162396,
CC       ECO:0000269|PubMed:18260615, ECO:0000269|PubMed:18266323,
CC       ECO:0000269|PubMed:18359629, ECO:0000269|PubMed:18374572,
CC       ECO:0000269|PubMed:18461940, ECO:0000269|PubMed:18481843,
CC       ECO:0000269|PubMed:18640037, ECO:0000269|PubMed:18723489,
CC       ECO:0000269|PubMed:18768466, ECO:0000269|PubMed:1909891,
CC       ECO:0000269|PubMed:19115843, ECO:0000269|PubMed:19170619,
CC       ECO:0000269|PubMed:19186056, ECO:0000269|PubMed:19206230,
CC       ECO:0000269|PubMed:1932029, ECO:0000269|PubMed:19520834,
CC       ECO:0000269|PubMed:19583303, ECO:0000269|PubMed:19731956,
CC       ECO:0000269|PubMed:19778001, ECO:0000269|PubMed:19827837,
CC       ECO:0000269|PubMed:3151019, ECO:0000269|PubMed:3151020,
CC       ECO:0000269|PubMed:7608893, ECO:0000269|PubMed:7696263,
CC       ECO:0000269|PubMed:7761440, ECO:0000269|PubMed:7803386,
CC       ECO:0000269|PubMed:7901850, ECO:0000269|PubMed:8070585,
CC       ECO:0000269|PubMed:8142888, ECO:0000269|PubMed:8218160,
CC       ECO:0000269|PubMed:8262987, ECO:0000269|PubMed:8331673,
CC       ECO:0000269|PubMed:8399159, ECO:0000269|PubMed:8431430,
CC       ECO:0000269|PubMed:8451242, ECO:0000269|PubMed:8482389,
CC       ECO:0000269|PubMed:8557623, ECO:0000269|PubMed:8639494,
CC       ECO:0000269|PubMed:8987974, ECO:0000269|PubMed:9265618,
CC       ECO:0000269|PubMed:9398308, ECO:0000269|PubMed:9541386,
CC       ECO:0000269|PubMed:9865942}.
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:15990874}.
CC       Cell membrane {ECO:0000269|PubMed:15990874}. Note=Colocalized with
CC       SLC26A6 at the surface of the cell membrane in order to form a
CC       bicarbonate transport metabolon. Displaced from the cytosolic
CC       surface of the cell membrane by PKC in phorbol myristate acetate
CC       (PMA)-induced cells.
CC   -!- DISEASE: Osteopetrosis, autosomal recessive 3 (OPTB3)
CC       [MIM:259730]: A rare genetic disease characterized by abnormally
CC       dense bone, due to defective resorption of immature bone.
CC       Osteopetrosis occurs in two forms: a severe autosomal recessive
CC       form occurring in utero, infancy, or childhood, and a benign
CC       autosomal dominant form occurring in adolescence or adulthood.
CC       Recessive osteopetrosis commonly manifests in early infancy with
CC       macrocephaly, feeding difficulties, evolving blindness and
CC       deafness, bone marrow failure, severe anemia, and
CC       hepatosplenomegaly. Deafness and blindness are generally thought
CC       to represent effects of pressure on nerves. OPTB3 is associated
CC       with renal tubular acidosis, cerebral calcification (marble brain
CC       disease) and in some cases with mental retardation.
CC       {ECO:0000269|PubMed:15300855, ECO:0000269|PubMed:1542674,
CC       ECO:0000269|PubMed:1928091, ECO:0000269|PubMed:8834238,
CC       ECO:0000269|PubMed:9143915}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- MISCELLANEOUS: Target of drugs used in treatments against glaucoma
CC       disorder and breast cancer.
CC   -!- SIMILARITY: Belongs to the alpha-carbonic anhydrase family.
CC       {ECO:0000305}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; M77181; AAA51909.1; -; Genomic_DNA.
DR   EMBL; M77176; AAA51909.1; JOINED; Genomic_DNA.
DR   EMBL; M77177; AAA51909.1; JOINED; Genomic_DNA.
DR   EMBL; M77178; AAA51909.1; JOINED; Genomic_DNA.
DR   EMBL; M77179; AAA51909.1; JOINED; Genomic_DNA.
DR   EMBL; M77180; AAA51909.1; JOINED; Genomic_DNA.
DR   EMBL; Y00339; CAA68426.1; -; mRNA.
DR   EMBL; X03251; CAA27012.1; -; Genomic_DNA.
DR   EMBL; J03037; AAA51908.1; -; mRNA.
DR   EMBL; CR536526; CAG38763.1; -; mRNA.
DR   EMBL; CR541875; CAG46673.1; -; mRNA.
DR   EMBL; AK312978; BAG35815.1; -; mRNA.
DR   EMBL; CH471068; EAW87136.1; -; Genomic_DNA.
DR   EMBL; BC011949; AAH11949.1; -; mRNA.
DR   EMBL; M36532; AAA51911.1; -; mRNA.
DR   CCDS; CCDS6239.1; -.
DR   PIR; A27175; CRHU2.
DR   RefSeq; NP_000058.1; NM_000067.2.
DR   UniGene; Hs.155097; -.
DR   PDB; 12CA; X-ray; 2.40 A; A=1-260.
DR   PDB; 1A42; X-ray; 2.25 A; A=2-260.
DR   PDB; 1AM6; X-ray; 2.00 A; A=2-260.
DR   PDB; 1AVN; X-ray; 2.00 A; A=2-260.
DR   PDB; 1BCD; X-ray; 1.90 A; A=2-260.
DR   PDB; 1BIC; X-ray; 1.90 A; A=2-260.
DR   PDB; 1BN1; X-ray; 2.10 A; A=2-260.
DR   PDB; 1BN3; X-ray; 2.20 A; A=2-260.
DR   PDB; 1BN4; X-ray; 2.10 A; A=2-260.
DR   PDB; 1BNM; X-ray; 2.60 A; A=2-260.
DR   PDB; 1BNN; X-ray; 2.30 A; A=2-260.
DR   PDB; 1BNQ; X-ray; 2.40 A; A=2-260.
DR   PDB; 1BNT; X-ray; 2.15 A; A=2-260.
DR   PDB; 1BNU; X-ray; 2.15 A; A=2-260.
DR   PDB; 1BNV; X-ray; 2.40 A; A=2-260.
DR   PDB; 1BNW; X-ray; 2.25 A; A=2-260.
DR   PDB; 1BV3; X-ray; 1.85 A; A=2-260.
DR   PDB; 1CA2; X-ray; 2.00 A; A=2-260.
DR   PDB; 1CA3; X-ray; 2.30 A; A=1-260.
DR   PDB; 1CAH; X-ray; 1.88 A; A=2-260.
DR   PDB; 1CAI; X-ray; 1.80 A; A=2-260.
DR   PDB; 1CAJ; X-ray; 1.90 A; A=2-260.
DR   PDB; 1CAK; X-ray; 1.90 A; A=2-260.
DR   PDB; 1CAL; X-ray; 2.20 A; A=2-260.
DR   PDB; 1CAM; X-ray; 1.70 A; A=2-260.
DR   PDB; 1CAN; X-ray; 1.90 A; A=2-260.
DR   PDB; 1CAO; X-ray; 1.90 A; A=2-260.
DR   PDB; 1CAY; X-ray; 2.10 A; A=2-260.
DR   PDB; 1CAZ; X-ray; 1.90 A; A=2-260.
DR   PDB; 1CCS; X-ray; 2.35 A; A=2-260.
DR   PDB; 1CCT; X-ray; 2.20 A; A=2-260.
DR   PDB; 1CCU; X-ray; 2.25 A; A=2-260.
DR   PDB; 1CIL; X-ray; 1.60 A; A=2-260.
DR   PDB; 1CIM; X-ray; 2.10 A; A=2-260.
DR   PDB; 1CIN; X-ray; 2.10 A; A=2-260.
DR   PDB; 1CNB; X-ray; 2.35 A; A=2-260.
DR   PDB; 1CNC; X-ray; 2.20 A; A=2-260.
DR   PDB; 1CNG; X-ray; 1.90 A; A=2-260.
DR   PDB; 1CNH; X-ray; 2.05 A; A=2-260.
DR   PDB; 1CNI; X-ray; 1.80 A; A=2-260.
DR   PDB; 1CNJ; X-ray; 1.80 A; A=2-260.
DR   PDB; 1CNK; X-ray; 2.15 A; A=2-260.
DR   PDB; 1CNW; X-ray; 2.00 A; A=1-260.
DR   PDB; 1CNX; X-ray; 1.90 A; A=1-260.
DR   PDB; 1CNY; X-ray; 2.30 A; A=1-260.
DR   PDB; 1CRA; X-ray; 1.90 A; A=2-260.
DR   PDB; 1CVA; X-ray; 2.25 A; A=2-260.
DR   PDB; 1CVB; X-ray; 2.40 A; A=2-260.
DR   PDB; 1CVC; X-ray; 2.30 A; A=2-260.
DR   PDB; 1CVD; X-ray; 2.20 A; A=5-259.
DR   PDB; 1CVE; X-ray; 2.25 A; A=2-260.
DR   PDB; 1CVF; X-ray; 2.25 A; A=2-260.
DR   PDB; 1CVH; X-ray; 2.30 A; A=5-259.
DR   PDB; 1DCA; X-ray; 2.20 A; A=1-260.
DR   PDB; 1DCB; X-ray; 2.10 A; A=1-260.
DR   PDB; 1EOU; X-ray; 2.10 A; A=1-260.
DR   PDB; 1F2W; X-ray; 1.90 A; A=2-260.
DR   PDB; 1FQL; X-ray; 2.00 A; A=1-260.
DR   PDB; 1FQM; X-ray; 2.00 A; A=1-260.
DR   PDB; 1FQN; X-ray; 2.00 A; A=1-260.
DR   PDB; 1FQR; X-ray; 2.00 A; A=1-260.
DR   PDB; 1FR4; X-ray; 1.60 A; A=1-260.
DR   PDB; 1FR7; X-ray; 1.50 A; A/B=1-260.
DR   PDB; 1FSN; X-ray; 2.00 A; A/B=1-260.
DR   PDB; 1FSQ; X-ray; 2.00 A; A/B=1-260.
DR   PDB; 1FSR; X-ray; 2.00 A; A/B=1-260.
DR   PDB; 1G0E; X-ray; 1.60 A; A=1-260.
DR   PDB; 1G0F; X-ray; 1.60 A; A=1-260.
DR   PDB; 1G1D; X-ray; 2.04 A; A=2-260.
DR   PDB; 1G3Z; X-ray; 1.86 A; A=2-260.
DR   PDB; 1G45; X-ray; 1.83 A; A=2-260.
DR   PDB; 1G46; X-ray; 1.84 A; A=2-260.
DR   PDB; 1G48; X-ray; 1.86 A; A=2-260.
DR   PDB; 1G4J; X-ray; 1.84 A; A=2-260.
DR   PDB; 1G4O; X-ray; 1.96 A; A=2-260.
DR   PDB; 1G52; X-ray; 1.80 A; A=2-260.
DR   PDB; 1G53; X-ray; 1.94 A; A=2-260.
DR   PDB; 1G54; X-ray; 1.86 A; A=2-260.
DR   PDB; 1H4N; X-ray; 2.00 A; A=2-260.
DR   PDB; 1H9N; X-ray; 1.85 A; A=2-260.
DR   PDB; 1H9Q; X-ray; 2.20 A; A=2-260.
DR   PDB; 1HCA; X-ray; 2.30 A; A=1-260.
DR   PDB; 1HEA; X-ray; 2.00 A; A=1-260.
DR   PDB; 1HEB; X-ray; 2.00 A; A=1-260.
DR   PDB; 1HEC; X-ray; 2.00 A; A=1-260.
DR   PDB; 1HED; X-ray; 2.00 A; A=1-260.
DR   PDB; 1HVA; X-ray; 2.30 A; A=1-260.
DR   PDB; 1I8Z; X-ray; 1.93 A; A=2-260.
DR   PDB; 1I90; X-ray; 2.00 A; A=2-260.
DR   PDB; 1I91; X-ray; 2.00 A; A=2-260.
DR   PDB; 1I9L; X-ray; 1.93 A; A=2-260.
DR   PDB; 1I9M; X-ray; 1.84 A; A=2-260.
DR   PDB; 1I9N; X-ray; 1.86 A; A=2-260.
DR   PDB; 1I9O; X-ray; 1.86 A; A=2-260.
DR   PDB; 1I9P; X-ray; 1.92 A; A=2-260.
DR   PDB; 1I9Q; X-ray; 1.80 A; A=2-260.
DR   PDB; 1IF4; X-ray; 1.93 A; A=2-260.
DR   PDB; 1IF5; X-ray; 2.00 A; A=2-260.
DR   PDB; 1IF6; X-ray; 2.09 A; A=2-259.
DR   PDB; 1IF7; X-ray; 1.98 A; A=2-260.
DR   PDB; 1IF8; X-ray; 1.94 A; A=2-260.
DR   PDB; 1IF9; X-ray; 2.00 A; A=2-260.
DR   PDB; 1KWQ; X-ray; 2.60 A; A=1-260.
DR   PDB; 1KWR; X-ray; 2.25 A; A=1-260.
DR   PDB; 1LG5; X-ray; 1.75 A; A=1-260.
DR   PDB; 1LG6; X-ray; 2.20 A; A=1-260.
DR   PDB; 1LGD; X-ray; 1.90 A; A=1-260.
DR   PDB; 1LUG; X-ray; 0.95 A; A=2-260.
DR   PDB; 1LZV; X-ray; 2.30 A; A=1-260.
DR   PDB; 1MOO; X-ray; 1.05 A; A=1-260.
DR   PDB; 1MUA; X-ray; 1.70 A; A=4-259.
DR   PDB; 1OKL; X-ray; 2.10 A; A=2-260.
DR   PDB; 1OKM; X-ray; 2.20 A; A=2-260.
DR   PDB; 1OKN; X-ray; 2.40 A; A=2-260.
DR   PDB; 1OQ5; X-ray; 1.50 A; A=2-259.
DR   PDB; 1RAY; X-ray; 1.80 A; A=2-260.
DR   PDB; 1RAZ; X-ray; 1.90 A; A=2-260.
DR   PDB; 1RZA; X-ray; 1.90 A; A=2-260.
DR   PDB; 1RZB; X-ray; 1.80 A; A=2-260.
DR   PDB; 1RZC; X-ray; 1.90 A; A=2-260.
DR   PDB; 1RZD; X-ray; 1.90 A; A=2-260.
DR   PDB; 1RZE; X-ray; 1.90 A; A=2-260.
DR   PDB; 1T9N; X-ray; 2.00 A; A=1-259.
DR   PDB; 1TB0; X-ray; 2.00 A; X=1-259.
DR   PDB; 1TBT; X-ray; 2.00 A; X=1-259.
DR   PDB; 1TE3; X-ray; 2.00 A; X=1-260.
DR   PDB; 1TEQ; X-ray; 2.00 A; X=1-260.
DR   PDB; 1TEU; X-ray; 2.00 A; X=1-260.
DR   PDB; 1TG3; X-ray; 1.80 A; A=1-260.
DR   PDB; 1TG9; X-ray; 1.90 A; A=1-260.
DR   PDB; 1TH9; X-ray; 1.63 A; A=1-260.
DR   PDB; 1THK; X-ray; 1.80 A; A=1-260.
DR   PDB; 1TTM; X-ray; 1.95 A; A=2-259.
DR   PDB; 1UGA; X-ray; 2.00 A; A=3-260.
DR   PDB; 1UGB; X-ray; 2.00 A; A=3-260.
DR   PDB; 1UGC; X-ray; 2.00 A; A=3-260.
DR   PDB; 1UGD; X-ray; 2.00 A; A=3-260.
DR   PDB; 1UGE; X-ray; 1.90 A; A=3-260.
DR   PDB; 1UGF; X-ray; 2.00 A; A=3-260.
DR   PDB; 1UGG; X-ray; 2.20 A; A=3-260.
DR   PDB; 1XEG; X-ray; 1.81 A; A=1-260.
DR   PDB; 1XEV; X-ray; 2.20 A; A/B/C/D=1-260.
DR   PDB; 1XPZ; X-ray; 2.02 A; A=3-260.
DR   PDB; 1XQ0; X-ray; 1.76 A; A=2-260.
DR   PDB; 1YDA; X-ray; 2.10 A; A=2-260.
DR   PDB; 1YDB; X-ray; 1.90 A; A=2-260.
DR   PDB; 1YDC; X-ray; 1.95 A; A=2-260.
DR   PDB; 1YDD; X-ray; 2.10 A; A=2-260.
DR   PDB; 1YO0; X-ray; 1.80 A; A=1-260.
DR   PDB; 1YO1; X-ray; 1.70 A; A=1-260.
DR   PDB; 1YO2; X-ray; 1.80 A; A=1-259.
DR   PDB; 1Z9Y; X-ray; 1.66 A; A=2-259.
DR   PDB; 1ZE8; X-ray; 2.00 A; A=2-260.
DR   PDB; 1ZFK; X-ray; 1.56 A; A=2-259.
DR   PDB; 1ZFQ; X-ray; 1.55 A; A=2-259.
DR   PDB; 1ZGE; X-ray; 1.65 A; A=2-259.
DR   PDB; 1ZGF; X-ray; 1.75 A; A=2-259.
DR   PDB; 1ZH9; X-ray; 1.70 A; A=2-259.
DR   PDB; 1ZSA; X-ray; 2.50 A; A=2-260.
DR   PDB; 1ZSB; X-ray; 2.00 A; A=2-260.
DR   PDB; 1ZSC; X-ray; 1.80 A; A=2-260.
DR   PDB; 2ABE; X-ray; 2.00 A; A=2-259.
DR   PDB; 2AW1; X-ray; 1.46 A; A=2-260.
DR   PDB; 2AX2; X-ray; 1.50 A; A=1-259.
DR   PDB; 2CA2; X-ray; 1.90 A; A=2-260.
DR   PDB; 2CBA; X-ray; 1.54 A; A=2-260.
DR   PDB; 2CBB; X-ray; 1.67 A; A=2-260.
DR   PDB; 2CBC; X-ray; 1.88 A; A=2-260.
DR   PDB; 2CBD; X-ray; 1.67 A; A=2-260.
DR   PDB; 2CBE; X-ray; 1.82 A; A=2-260.
DR   PDB; 2EU2; X-ray; 1.15 A; A=1-260.
DR   PDB; 2EU3; X-ray; 1.60 A; A=1-260.
DR   PDB; 2EZ7; X-ray; 2.00 A; A=1-259.
DR   PDB; 2F14; X-ray; 1.71 A; A=2-259.
DR   PDB; 2FMG; X-ray; 1.60 A; A=1-259.
DR   PDB; 2FMZ; X-ray; 1.60 A; A=1-259.
DR   PDB; 2FNK; X-ray; 1.80 A; A=1-260.
DR   PDB; 2FNM; X-ray; 1.80 A; A=1-260.
DR   PDB; 2FNN; X-ray; 1.80 A; A=1-260.
DR   PDB; 2FOQ; X-ray; 1.25 A; A=1-259.
DR   PDB; 2FOS; X-ray; 1.10 A; A=1-259.
DR   PDB; 2FOU; X-ray; 0.99 A; A=1-259.
DR   PDB; 2FOV; X-ray; 1.15 A; A=1-259.
DR   PDB; 2GD8; X-ray; 1.46 A; A=2-259.
DR   PDB; 2GEH; X-ray; 2.00 A; A=1-259.
DR   PDB; 2H15; X-ray; 1.90 A; A=1-259.
DR   PDB; 2H4N; X-ray; 1.90 A; A=2-260.
DR   PDB; 2HD6; X-ray; 1.80 A; A=2-259.
DR   PDB; 2HKK; X-ray; 1.90 A; A=1-260.
DR   PDB; 2HL4; X-ray; 1.55 A; A=2-260.
DR   PDB; 2HNC; X-ray; 1.55 A; A=2-259.
DR   PDB; 2HOC; X-ray; 2.10 A; A=2-259.
DR   PDB; 2ILI; X-ray; 1.05 A; A=2-259.
DR   PDB; 2NNG; X-ray; 1.20 A; A=2-260.
DR   PDB; 2NNO; X-ray; 1.01 A; A=2-260.
DR   PDB; 2NNS; X-ray; 1.03 A; A=2-260.
DR   PDB; 2NNV; X-ray; 1.10 A; A=2-260.
DR   PDB; 2NWO; X-ray; 1.70 A; A=1-259.
DR   PDB; 2NWP; X-ray; 1.80 A; A=1-259.
DR   PDB; 2NWY; X-ray; 1.65 A; A=1-259.
DR   PDB; 2NWZ; X-ray; 1.80 A; A=1-259.
DR   PDB; 2NXR; X-ray; 1.70 A; A=1-259.
DR   PDB; 2NXS; X-ray; 1.80 A; A=1-259.
DR   PDB; 2NXT; X-ray; 1.15 A; A=1-260.
DR   PDB; 2O4Z; X-ray; 2.10 A; A=1-260.
DR   PDB; 2OSF; X-ray; 1.60 A; A=2-260.
DR   PDB; 2OSM; X-ray; 1.60 A; A=2-260.
DR   PDB; 2POU; X-ray; 1.60 A; A=1-259.
DR   PDB; 2POV; X-ray; 1.60 A; A=1-258.
DR   PDB; 2POW; X-ray; 1.75 A; A=1-259.
DR   PDB; 2Q1B; X-ray; 1.70 A; A=1-260.
DR   PDB; 2Q1Q; X-ray; 1.90 A; A=1-260.
DR   PDB; 2Q38; X-ray; 1.95 A; A=1-260.
DR   PDB; 2QO8; X-ray; 1.40 A; A=2-260.
DR   PDB; 2QOA; X-ray; 1.60 A; A=2-260.
DR   PDB; 2QP6; X-ray; 1.45 A; A=2-260.
DR   PDB; 2VVA; X-ray; 1.56 A; X=1-260.
DR   PDB; 2VVB; X-ray; 1.66 A; X=1-260.
DR   PDB; 2WD2; X-ray; 1.49 A; A=2-259.
DR   PDB; 2WD3; X-ray; 1.80 A; A=2-260.
DR   PDB; 2WEG; X-ray; 1.10 A; A=2-260.
DR   PDB; 2WEH; X-ray; 2.09 A; A=2-260.
DR   PDB; 2WEJ; X-ray; 1.45 A; A=2-260.
DR   PDB; 2WEO; X-ray; 1.40 A; A=2-260.
DR   PDB; 2X7S; X-ray; 1.64 A; A=2-260.
DR   PDB; 2X7T; X-ray; 1.89 A; A=2-260.
DR   PDB; 2X7U; X-ray; 2.12 A; A=2-260.
DR   PDB; 3B4F; X-ray; 1.89 A; A=1-260.
DR   PDB; 3BET; X-ray; 1.85 A; A=2-260.
DR   PDB; 3BL0; X-ray; 1.90 A; A=1-260.
DR   PDB; 3BL1; X-ray; 2.10 A; A=1-260.
DR   PDB; 3C7P; X-ray; 1.70 A; A=1-260.
DR   PDB; 3CA2; X-ray; 2.00 A; A=2-260.
DR   PDB; 3CAJ; X-ray; 1.80 A; A=1-260.
DR   PDB; 3CYU; X-ray; 1.70 A; A=1-260.
DR   PDB; 3D8W; X-ray; 1.70 A; A=1-260.
DR   PDB; 3D92; X-ray; 1.10 A; A=1-260.
DR   PDB; 3D93; X-ray; 1.10 A; A=1-260.
DR   PDB; 3D9Z; X-ray; 1.65 A; A=1-260.
DR   PDB; 3DAZ; X-ray; 1.60 A; A=1-260.
DR   PDB; 3DBU; X-ray; 1.70 A; A=1-260.
DR   PDB; 3DC3; X-ray; 1.70 A; A=1-260.
DR   PDB; 3DC9; X-ray; 1.60 A; A=1-260.
DR   PDB; 3DCC; X-ray; 1.60 A; A=1-260.
DR   PDB; 3DCS; X-ray; 1.80 A; A=1-260.
DR   PDB; 3DCW; X-ray; 1.50 A; A=1-260.
DR   PDB; 3DD0; X-ray; 1.48 A; A=1-260.
DR   PDB; 3DD8; X-ray; 1.90 A; A=1-260.
DR   PDB; 3DV7; X-ray; 1.70 A; A=2-260.
DR   PDB; 3DVB; X-ray; 1.70 A; A=2-260.
DR   PDB; 3DVC; X-ray; 1.60 A; A=2-260.
DR   PDB; 3DVD; X-ray; 1.60 A; A=2-260.
DR   PDB; 3EFI; X-ray; 1.75 A; A=2-260.
DR   PDB; 3EFT; X-ray; 1.85 A; A=1-260.
DR   PDB; 3F4X; X-ray; 1.90 A; A=1-260.
DR   PDB; 3F8E; X-ray; 2.00 A; A=1-260.
DR   PDB; 3FFP; X-ray; 1.81 A; X=1-260.
DR   PDB; 3GZ0; X-ray; 1.26 A; A=2-260.
DR   PDB; 3HFP; X-ray; 2.10 A; A=1-260.
DR   PDB; 3HKN; X-ray; 1.80 A; A=1-260.
DR   PDB; 3HKQ; X-ray; 1.70 A; A=1-260.
DR   PDB; 3HKT; X-ray; 2.36 A; A=1-260.
DR   PDB; 3HKU; X-ray; 1.80 A; A=1-260.
DR   PDB; 3HLJ; X-ray; 1.44 A; A=1-260.
DR   PDB; 3HS4; X-ray; 1.10 A; A=1-260.
DR   PDB; 3IBI; X-ray; 1.93 A; A=2-260.
DR   PDB; 3IBL; X-ray; 1.55 A; A=2-260.
DR   PDB; 3IBN; X-ray; 2.20 A; A=2-260.
DR   PDB; 3IBU; X-ray; 1.41 A; A=2-260.
DR   PDB; 3IEO; X-ray; 2.00 A; A=1-260.
DR   PDB; 3IGP; X-ray; 1.65 A; A=1-260.
DR   PDB; 3K2F; X-ray; 1.98 A; A=1-260.
DR   PDB; 3K34; X-ray; 0.90 A; A=1-260.
DR   PDB; 3K7K; X-ray; 1.90 A; A=1-260.
DR   PDB; 3KIG; X-ray; 1.39 A; A=1-260.
DR   PDB; 3KKX; Neutron; 2.00 A; A=1-260.
DR   PDB; 3KNE; X-ray; 1.35 A; A=1-260.
DR   PDB; 3KOI; X-ray; 1.64 A; A=1-260.
DR   PDB; 3KOK; X-ray; 1.50 A; A=1-260.
DR   PDB; 3KON; X-ray; 1.50 A; A=1-260.
DR   PDB; 3KS3; X-ray; 0.90 A; A=1-260.
DR   PDB; 3KWA; X-ray; 2.00 A; A=1-260.
DR   PDB; 3L14; X-ray; 1.22 A; A=1-260.
DR   PDB; 3M04; X-ray; 1.40 A; A=1-260.
DR   PDB; 3M14; X-ray; 1.38 A; A=1-260.
DR   PDB; 3M1J; X-ray; 1.80 A; A=1-260.
DR   PDB; 3M1K; X-ray; 1.35 A; A=1-260.
DR   PDB; 3M1Q; X-ray; 1.69 A; A=1-260.
DR   PDB; 3M1W; X-ray; 1.38 A; A=1-260.
DR   PDB; 3M2N; X-ray; 1.65 A; A=1-260.
DR   PDB; 3M2X; X-ray; 1.87 A; A=1-260.
DR   PDB; 3M2Y; X-ray; 1.17 A; A=1-260.
DR   PDB; 3M2Z; X-ray; 1.70 A; A=1-260.
DR   PDB; 3M3X; X-ray; 1.68 A; A=1-260.
DR   PDB; 3M40; X-ray; 1.60 A; A=1-260.
DR   PDB; 3M5E; X-ray; 1.70 A; A=1-260.
DR   PDB; 3M5S; X-ray; 1.40 A; A=1-260.
DR   PDB; 3M5T; X-ray; 1.95 A; A=1-260.
DR   PDB; 3M67; X-ray; 1.80 A; A=1-260.
DR   PDB; 3M96; X-ray; 1.40 A; A=1-260.
DR   PDB; 3M98; X-ray; 1.50 A; A=1-260.
DR   PDB; 3MHC; X-ray; 1.70 A; A=1-260.
DR   PDB; 3MHI; X-ray; 1.70 A; A=1-260.
DR   PDB; 3MHL; X-ray; 1.90 A; A=1-260.
DR   PDB; 3MHM; X-ray; 1.50 A; A=1-260.
DR   PDB; 3MHO; X-ray; 1.15 A; A=1-260.
DR   PDB; 3ML2; X-ray; 1.80 A; A=1-260.
DR   PDB; 3MMF; X-ray; 1.50 A; A=1-260.
DR   PDB; 3MNA; X-ray; 1.50 A; A=1-260.
DR   PDB; 3MNH; X-ray; 1.65 A; A=1-260.
DR   PDB; 3MNI; X-ray; 1.75 A; A=1-260.
DR   PDB; 3MNJ; X-ray; 1.75 A; A=1-260.
DR   PDB; 3MNK; X-ray; 1.75 A; A=1-260.
DR   PDB; 3MNU; X-ray; 1.80 A; A=2-260.
DR   PDB; 3MWO; X-ray; 1.40 A; A/B=1-260.
DR   PDB; 3MYQ; X-ray; 1.35 A; A=1-260.
DR   PDB; 3MZC; X-ray; 1.50 A; A=1-260.
DR   PDB; 3N0N; X-ray; 1.50 A; A=1-260.
DR   PDB; 3N2P; X-ray; 1.65 A; A=1-260.
DR   PDB; 3N3J; X-ray; 1.50 A; A=1-260.
DR   PDB; 3N4B; X-ray; 1.60 A; A=1-260.
DR   PDB; 3NB5; X-ray; 1.80 A; A=1-260.
DR   PDB; 3NI5; X-ray; 2.10 A; A=1-260.
DR   PDB; 3NJ9; X-ray; 2.00 A; A=1-260.
DR   PDB; 3OIK; X-ray; 1.50 A; A=1-260.
DR   PDB; 3OIL; X-ray; 1.50 A; A=1-260.
DR   PDB; 3OIM; X-ray; 1.45 A; A=1-260.
DR   PDB; 3OKU; X-ray; 1.45 A; A=1-260.
DR   PDB; 3OKV; X-ray; 1.45 A; A=1-260.
DR   PDB; 3OY0; X-ray; 1.60 A; A=1-260.
DR   PDB; 3OYQ; X-ray; 1.47 A; A=1-260.
DR   PDB; 3OYS; X-ray; 1.54 A; A=1-260.
DR   PDB; 3P3H; X-ray; 1.50 A; A=1-260.
DR   PDB; 3P3J; X-ray; 1.60 A; A=1-260.
DR   PDB; 3P44; X-ray; 2.20 A; A=1-260.
DR   PDB; 3P4V; X-ray; 2.00 A; A=1-260.
DR   PDB; 3P55; X-ray; 2.00 A; A=1-260.
DR   PDB; 3P58; X-ray; 1.49 A; A=1-260.
DR   PDB; 3P5A; X-ray; 1.49 A; A=1-260.
DR   PDB; 3P5L; X-ray; 1.50 A; A=1-260.
DR   PDB; 3PJJ; X-ray; 1.80 A; A=2-260.
DR   PDB; 3PO6; X-ray; 1.47 A; A=2-260.
DR   PDB; 3PYK; X-ray; 1.30 A; A=1-260.
DR   PDB; 3QYK; X-ray; 1.47 A; A=1-260.
DR   PDB; 3R16; X-ray; 1.60 A; A=4-260.
DR   PDB; 3R17; X-ray; 1.70 A; B=4-260.
DR   PDB; 3RG3; X-ray; 1.90 A; A=1-260.
DR   PDB; 3RG4; X-ray; 1.50 A; A=1-260.
DR   PDB; 3RGE; X-ray; 2.10 A; A=1-260.
DR   PDB; 3RJ7; X-ray; 1.20 A; A=3-260.
DR   PDB; 3RLD; X-ray; 1.50 A; A=1-260.
DR   PDB; 3RYJ; X-ray; 1.39 A; B=2-260.
DR   PDB; 3RYV; X-ray; 1.20 A; B=2-260.
DR   PDB; 3RYX; X-ray; 1.60 A; B=2-260.
DR   PDB; 3RYY; X-ray; 1.16 A; A=2-260.
DR   PDB; 3RYZ; X-ray; 1.37 A; A=2-260.
DR   PDB; 3RZ0; X-ray; 1.80 A; B=2-260.
DR   PDB; 3RZ1; X-ray; 1.51 A; B=2-260.
DR   PDB; 3RZ5; X-ray; 1.65 A; A=2-260.
DR   PDB; 3RZ7; X-ray; 1.80 A; A=2-260.
DR   PDB; 3RZ8; X-ray; 1.70 A; A=2-260.
DR   PDB; 3S71; X-ray; 1.25 A; B=3-260.
DR   PDB; 3S72; X-ray; 1.60 A; B=3-260.
DR   PDB; 3S73; X-ray; 1.75 A; B=3-260.
DR   PDB; 3S74; X-ray; 1.40 A; B=3-260.
DR   PDB; 3S75; X-ray; 1.50 A; B=3-260.
DR   PDB; 3S76; X-ray; 1.60 A; A=3-260.
DR   PDB; 3S77; X-ray; 1.86 A; B=3-260.
DR   PDB; 3S78; X-ray; 1.98 A; B=3-260.
DR   PDB; 3S8X; X-ray; 1.30 A; A=1-260.
DR   PDB; 3S9T; X-ray; 1.30 A; A=1-260.
DR   PDB; 3SAP; X-ray; 1.75 A; A=1-260.
DR   PDB; 3SAX; X-ray; 1.10 A; A=1-260.
DR   PDB; 3SBH; X-ray; 1.65 A; A=1-260.
DR   PDB; 3SBI; X-ray; 1.40 A; A=1-260.
DR   PDB; 3T5U; X-ray; 1.75 A; A=2-260.
DR   PDB; 3T5Z; X-ray; 1.65 A; A=2-260.
DR   PDB; 3T82; X-ray; 2.00 A; A=1-260.
DR   PDB; 3T83; X-ray; 1.80 A; A=1-260.
DR   PDB; 3T84; X-ray; 2.00 A; A=1-260.
DR   PDB; 3T85; X-ray; 2.40 A; A=1-260.
DR   PDB; 3TMJ; Other; 2.00 A; A=3-260.
DR   PDB; 3TVN; X-ray; 1.50 A; X=3-260.
DR   PDB; 3TVO; X-ray; 1.60 A; X=3-260.
DR   PDB; 3U3A; X-ray; 1.55 A; X=1-260.
DR   PDB; 3U45; X-ray; 1.70 A; X=1-260.
DR   PDB; 3U47; X-ray; 1.60 A; A=1-260.
DR   PDB; 3U7C; X-ray; 0.93 A; A=1-260.
DR   PDB; 3V2J; X-ray; 1.70 A; A=1-260.
DR   PDB; 3V2M; X-ray; 1.47 A; A=1-260.
DR   PDB; 3V3F; X-ray; 2.00 A; A=1-260.
DR   PDB; 3V3G; X-ray; 1.56 A; B=1-260.
DR   PDB; 3V3H; X-ray; 1.85 A; B=1-260.
DR   PDB; 3V3I; X-ray; 1.73 A; B=1-260.
DR   PDB; 3V3J; X-ray; 1.63 A; A=1-260.
DR   PDB; 3V5G; X-ray; 1.50 A; A=1-260.
DR   PDB; 3V7X; X-ray; 1.03 A; A=2-260.
DR   PDB; 3VBD; X-ray; 1.05 A; A=2-260.
DR   PDB; 3ZP9; X-ray; 1.31 A; A=1-260.
DR   PDB; 4BCW; X-ray; 1.50 A; A=4-260.
DR   PDB; 4BF1; X-ray; 1.35 A; A=2-260.
DR   PDB; 4BF6; X-ray; 1.82 A; A=2-260.
DR   PDB; 4CA2; X-ray; 2.10 A; A=1-260.
DR   PDB; 4CAC; X-ray; 2.20 A; A=2-260.
DR   PDB; 4CQ0; X-ray; 1.45 A; A=1-260.
DR   PDB; 4DZ7; X-ray; 1.49 A; A=1-260.
DR   PDB; 4DZ9; X-ray; 1.49 A; A=1-260.
DR   PDB; 4E3D; X-ray; 1.60 A; A=1-260.
DR   PDB; 4E3F; X-ray; 1.50 A; A=1-260.
DR   PDB; 4E3G; X-ray; 1.55 A; A=1-260.
DR   PDB; 4E3H; X-ray; 1.50 A; A=1-260.
DR   PDB; 4E49; X-ray; 1.45 A; A=1-260.
DR   PDB; 4E4A; X-ray; 1.45 A; A=1-260.
DR   PDB; 4E5Q; X-ray; 1.70 A; A=1-260.
DR   PDB; 4FIK; X-ray; 1.20 A; A=1-260.
DR   PDB; 4FL7; X-ray; 1.85 A; A=2-260.
DR   PDB; 4FPT; X-ray; 0.98 A; A=1-260.
DR   PDB; 4FRC; X-ray; 0.98 A; A=1-260.
DR   PDB; 4FU5; X-ray; 0.98 A; A=1-260.
DR   PDB; 4FVN; X-ray; 1.05 A; A=1-260.
DR   PDB; 4FVO; X-ray; 1.05 A; A=1-260.
DR   PDB; 4G0C; Neutron; 2.00 A; A=4-260.
DR   PDB; 4GL1; X-ray; 1.50 A; X=1-260.
DR   PDB; 4HBA; X-ray; 1.76 A; A=1-260.
DR   PDB; 4HEW; X-ray; 1.70 A; A=1-260.
DR   PDB; 4HEY; X-ray; 1.45 A; A=1-260.
DR   PDB; 4HEZ; X-ray; 1.34 A; A=1-260.
DR   PDB; 4HF3; X-ray; 1.15 A; A=1-260.
DR   PDB; 4HT0; X-ray; 1.60 A; A=1-260.
DR   PDB; 4IDR; X-ray; 1.60 A; X=3-260.
DR   PDB; 4ILX; X-ray; 1.60 A; A=4-260.
DR   PDB; 4ITO; X-ray; 1.16 A; A=1-260.
DR   PDB; 4ITP; X-ray; 1.70 A; A=4-260.
DR   PDB; 4IWZ; X-ray; 1.60 A; A=4-260.
DR   PDB; 4JS6; X-ray; 1.55 A; A=1-260.
DR   PDB; 4JSA; X-ray; 1.50 A; A=1-260.
DR   PDB; 4JSS; X-ray; 1.50 A; A=1-260.
DR   PDB; 4JSW; X-ray; 1.90 A; A=1-260.
DR   PDB; 4JSZ; X-ray; 1.90 A; A=1-260.
DR   PDB; 4K0S; X-ray; 1.80 A; A=4-260.
DR   PDB; 4K0T; X-ray; 1.78 A; A=4-260.
DR   PDB; 4K0Z; X-ray; 1.80 A; A=3-260.
DR   PDB; 4K13; X-ray; 1.60 A; A=4-260.
DR   PDB; 4K1Q; X-ray; 1.70 A; A=3-260.
DR   PDB; 4KAP; X-ray; 1.45 A; A=5-260.
DR   PDB; 4KNI; X-ray; 1.80 A; A=1-260.
DR   PDB; 4KNJ; X-ray; 2.00 A; A=1-260.
DR   PDB; 4KUV; X-ray; 1.35 A; A=5-260.
DR   PDB; 4KUW; X-ray; 1.55 A; A=4-260.
DR   PDB; 4KUY; X-ray; 1.65 A; A=4-260.
DR   PDB; 4KV0; X-ray; 1.55 A; A=4-260.
DR   PDB; 4L5U; X-ray; 2.05 A; A=1-260.
DR   PDB; 4L5V; X-ray; 1.63 A; A=1-260.
DR   PDB; 4L5W; X-ray; 1.70 A; A=1-260.
DR   PDB; 4LHI; X-ray; 1.60 A; A=1-260.
DR   PDB; 4LP6; X-ray; 2.15 A; A/B=1-260.
DR   PDB; 4M2R; X-ray; 1.99 A; A=4-260.
DR   PDB; 4M2U; X-ray; 2.00 A; A=4-260.
DR   PDB; 4M2V; X-ray; 1.72 A; A=4-260.
DR   PDB; 4M2W; X-ray; 1.66 A; A=4-260.
DR   PDB; 4MDG; X-ray; 1.35 A; A=3-260.
DR   PDB; 4MDL; X-ray; 1.52 A; A=3-260.
DR   PDB; 4MDM; X-ray; 1.55 A; A=3-260.
DR   PDB; 4MLT; X-ray; 2.00 A; A=1-260.
DR   PDB; 4MLX; X-ray; 1.65 A; A=1-260.
DR   PDB; 4MO8; X-ray; 1.85 A; A=1-260.
DR   PDB; 4MTY; X-ray; 1.00 A; A=1-260.
DR   PDB; 4N0X; X-ray; 1.63 A; B=1-260.
DR   PDB; 4N16; X-ray; 1.54 A; A=1-260.
DR   PDB; 4PQ7; X-ray; 1.85 A; A=1-260.
DR   PDB; 4PXX; X-ray; 1.85 A; A=1-260.
DR   PDB; 4PYX; X-ray; 1.80 A; A=1-260.
DR   PDB; 4PYY; X-ray; 1.75 A; A=1-260.
DR   PDB; 4PZH; X-ray; 1.06 A; A=1-260.
DR   PDB; 4Q06; X-ray; 1.15 A; A=1-260.
DR   PDB; 4Q07; X-ray; 1.15 A; A=1-260.
DR   PDB; 4Q08; X-ray; 1.07 A; A=1-260.
DR   PDB; 4Q09; X-ray; 1.20 A; A=1-260.
DR   PDB; 4Q49; Neutron; 1.80 A; A=1-260.
DR   PDB; 4Q6D; X-ray; 1.12 A; A=1-260.
DR   PDB; 4Q6E; X-ray; 1.12 A; A=1-260.
DR   PDB; 4Q78; X-ray; 1.00 A; A=3-260.
DR   PDB; 4Q7P; X-ray; 1.65 A; A=1-260.
DR   PDB; 4Q7S; X-ray; 1.80 A; A=1-260.
DR   PDB; 4Q7V; X-ray; 1.60 A; A=1-260.
DR   PDB; 4Q7W; X-ray; 1.45 A; A=1-260.
DR   PDB; 4Q81; X-ray; 1.55 A; A=1-260.
DR   PDB; 4Q83; X-ray; 1.55 A; A=1-260.
DR   PDB; 4Q87; X-ray; 1.55 A; A=1-260.
DR   PDB; 4Q8X; X-ray; 1.55 A; A=1-260.
DR   PDB; 4Q8Y; X-ray; 1.45 A; A=1-260.
DR   PDB; 4Q8Z; X-ray; 1.50 A; A=1-260.
DR   PDB; 4Q90; X-ray; 1.54 A; A=1-260.
DR   PDB; 4Q99; X-ray; 1.50 A; A=1-260.
DR   PDB; 4Q9Y; X-ray; 1.55 A; A=1-260.
DR   PDB; 4QEF; X-ray; 1.47 A; A=1-260.
DR   PDB; 4QIY; X-ray; 1.30 A; A/B/C/D=1-260.
DR   PDB; 4QJM; X-ray; 1.75 A; A=1-260.
DR   PDB; 4QK1; X-ray; 1.60 A; A=1-260.
DR   PDB; 4QK2; X-ray; 1.52 A; A=1-260.
DR   PDB; 4QK3; X-ray; 1.34 A; A=1-260.
DR   PDB; 4QSA; X-ray; 1.50 A; A=1-260.
DR   PDB; 4QSB; X-ray; 1.40 A; A=1-260.
DR   PDB; 4QSI; X-ray; 1.95 A; A=1-260.
DR   PDB; 4QTL; X-ray; 1.80 A; A=1-260.
DR   PDB; 4QY3; X-ray; 1.50 A; A=2-260.
DR   PDB; 4R59; X-ray; 1.65 A; A=1-260.
DR   PDB; 4R5A; X-ray; 1.64 A; A=1-260.
DR   PDB; 4R5B; X-ray; 1.50 A; A=1-260.
DR   PDB; 4RFC; X-ray; 1.65 A; A=1-260.
DR   PDB; 4RFD; X-ray; 1.63 A; A=1-260.
DR   PDB; 4RH2; X-ray; 1.30 A; A=1-260.
DR   PDB; 4RIU; X-ray; 1.65 A; A=1-260.
DR   PDB; 4RIV; X-ray; 1.63 A; A=1-260.
DR   PDB; 4RN4; X-ray; 1.53 A; A=1-260.
DR   PDB; 4RUX; X-ray; 1.14 A; A=1-260.
DR   PDB; 4RUY; X-ray; 1.14 A; A=1-260.
DR   PDB; 4RUZ; X-ray; 1.63 A; A=1-260.
DR   PDB; 4WL4; X-ray; 1.10 A; A=1-260.
DR   PDB; 4WW6; X-ray; 1.06 A; A=1-260.
DR   PDB; 4XE1; X-ray; 1.80 A; A=1-260.
DR   PDB; 4Y0J; Neutron; 2.00 A; A=3-260.
DR   PDB; 4YGJ; X-ray; 1.10 A; A=3-260.
DR   PDB; 4YGK; X-ray; 1.50 A; A=3-260.
DR   PDB; 4YGL; X-ray; 1.51 A; A=3-260.
DR   PDB; 4YGN; X-ray; 1.23 A; A=3-260.
DR   PDB; 4YVY; X-ray; 1.45 A; A=2-260.
DR   PDB; 4YWP; X-ray; 1.45 A; A=4-260.
DR   PDB; 4YX4; X-ray; 1.01 A; A=1-260.
DR   PDB; 4YXI; X-ray; 0.96 A; A=1-260.
DR   PDB; 4YXO; X-ray; 1.06 A; A=1-260.
DR   PDB; 4YXU; X-ray; 1.08 A; A=1-260.
DR   PDB; 4YYT; X-ray; 1.07 A; A=1-260.
DR   PDB; 4Z0Q; X-ray; 1.45 A; A=3-260.
DR   PDB; 4Z1E; X-ray; 2.01 A; A=2-260.
DR   PDB; 4Z1J; X-ray; 1.27 A; A=3-260.
DR   PDB; 4Z1K; X-ray; 1.35 A; A=4-260.
DR   PDB; 4Z1N; X-ray; 1.47 A; A=3-260.
DR   PDB; 4ZAO; X-ray; 1.80 A; A=1-257.
DR   PDB; 4ZWI; X-ray; 1.60 A; A=4-260.
DR   PDB; 4ZWX; X-ray; 1.70 A; A=4-260.
DR   PDB; 4ZWY; X-ray; 1.50 A; A=4-260.
DR   PDB; 4ZWZ; X-ray; 1.62 A; A=4-260.
DR   PDB; 4ZX0; X-ray; 1.60 A; A=4-260.
DR   PDB; 4ZX1; X-ray; 1.50 A; A=4-260.
DR   PDB; 5A6H; X-ray; 1.57 A; A=1-260.
DR   PDB; 5AMD; X-ray; 1.50 A; A=2-260.
DR   PDB; 5AMG; X-ray; 1.55 A; A=2-260.
DR   PDB; 5AML; X-ray; 1.36 A; A=2-260.
DR   PDB; 5BNL; X-ray; 2.00 A; A=4-260.
DR   PDB; 5BRU; X-ray; 1.60 A; A=3-260.
DR   PDB; 5BRV; X-ray; 1.60 A; A=3-260.
DR   PDB; 5BRW; X-ray; 1.40 A; A=1-260.
DR   PDB; 5BYI; X-ray; 1.15 A; A=1-260.
DR   PDB; 5C8I; Other; 1.56 A; A=1-260.
DR   PDB; 5CA2; X-ray; 2.10 A; A=1-260.
DR   PDB; 5CAC; X-ray; 2.20 A; A=2-260.
DR   PDB; 5CJL; X-ray; 1.20 A; A=4-260.
DR   PDB; 5CLU; X-ray; 1.55 A; A=4-260.
DR   PDB; 5DOG; X-ray; 1.70 A; A=1-260.
DR   PDB; 5DOH; X-ray; 1.05 A; A/B=1-260.
DR   PDB; 5DRS; X-ray; 1.10 A; A=1-260.
DR   PDB; 5DSI; X-ray; 1.20 A; A=1-260.
DR   PDB; 5DSJ; X-ray; 1.25 A; A=1-260.
DR   PDB; 5DSK; X-ray; 1.30 A; A=1-260.
DR   PDB; 5DSL; X-ray; 1.45 A; A=1-260.
DR   PDB; 5DSM; X-ray; 1.30 A; A=1-260.
DR   PDB; 5DSN; X-ray; 1.45 A; A=1-260.
DR   PDB; 5DSO; X-ray; 1.40 A; A=1-260.
DR   PDB; 5DSP; X-ray; 1.40 A; A=1-260.
DR   PDB; 5DSQ; X-ray; 1.50 A; A=1-260.
DR   PDB; 5DSR; X-ray; 1.30 A; A=1-260.
DR   PDB; 5E28; X-ray; 1.30 A; A=4-260.
DR   PDB; 5E2K; X-ray; 1.40 A; A=4-260.
DR   PDB; 5E2R; X-ray; 1.60 A; A=1-260.
DR   PDB; 5E2S; X-ray; 1.50 A; A=3-260.
DR   PDB; 5EH5; X-ray; 1.21 A; A=1-260.
DR   PDB; 5EH7; X-ray; 1.43 A; A=1-260.
DR   PDB; 5EH8; X-ray; 1.38 A; A=1-260.
DR   PDB; 5EHE; X-ray; 1.50 A; A=1-260.
DR   PDB; 5EHV; X-ray; 1.21 A; A=1-260.
DR   PDB; 5EHW; X-ray; 1.39 A; A=1-260.
DR   PDB; 5EIJ; X-ray; 1.99 A; A=4-260.
DR   PDB; 5EKH; X-ray; 1.34 A; A=1-260.
DR   PDB; 5EKJ; X-ray; 1.13 A; A=1-260.
DR   PDB; 5EKM; X-ray; 1.33 A; A=1-260.
DR   PDB; 5EOI; X-ray; 1.80 A; A=3-260.
DR   PDB; 5FDC; X-ray; 1.75 A; A=1-260.
DR   PDB; 5FDI; X-ray; 1.85 A; A=1-260.
DR   PDB; 5FLO; X-ray; 1.66 A; A=1-260.
DR   PDB; 5FLP; X-ray; 1.71 A; A=1-260.
DR   PDB; 5FLQ; X-ray; 1.70 A; A=1-260.
DR   PDB; 5FLR; X-ray; 1.68 A; A=1-260.
DR   PDB; 5FLS; X-ray; 1.67 A; A=1-260.
DR   PDB; 5FLT; X-ray; 1.67 A; A=1-260.
DR   PDB; 5FNG; X-ray; 2.05 A; A=1-260.
DR   PDB; 5FNH; X-ray; 1.66 A; A=1-260.
DR   PDB; 5FNI; X-ray; 1.60 A; A=1-260.
DR   PDB; 5FNJ; X-ray; 1.67 A; A=1-260.
DR   PDB; 5FNK; X-ray; 1.59 A; A=1-260.
DR   PDB; 5FNL; X-ray; 1.59 A; A=1-260.
DR   PDB; 5FNM; X-ray; 1.59 A; A=1-260.
DR   PDB; 5G01; X-ray; 1.40 A; A=1-260.
DR   PDB; 5G03; X-ray; 1.35 A; A=1-260.
DR   PDB; 5G0B; X-ray; 1.55 A; A=1-260.
DR   PDB; 5G0C; X-ray; 1.28 A; A=1-260.
DR   PDB; 5J8Z; X-ray; 1.70 A; A=1-260.
DR   PDB; 5JDV; X-ray; 1.34 A; B=3-260.
DR   PDB; 5JE7; X-ray; 1.15 A; B=4-260.
DR   PDB; 5JEG; X-ray; 1.19 A; B=3-260.
DR   PDB; 5JEH; X-ray; 1.13 A; B=3-260.
DR   PDB; 5JEP; X-ray; 1.19 A; B=3-260.
DR   PDB; 5JES; X-ray; 1.21 A; B=3-259.
DR   PDB; 5JG3; X-ray; 1.21 A; B=3-260.
DR   PDB; 5JG5; X-ray; 1.19 A; B=3-260.
DR   PDB; 5JGS; X-ray; 1.11 A; B=4-260.
DR   PDB; 5JGT; X-ray; 1.10 A; B=3-260.
DR   PDB; 5JQ0; X-ray; 1.40 A; A=1-260.
DR   PDB; 5JQT; X-ray; 1.36 A; A=1-260.
DR   PDB; 5L3O; X-ray; 1.98 A; A/B=1-260.
DR   PDB; 5L6K; X-ray; 1.70 A; A/B=1-260.
DR   PDB; 5LMD; X-ray; 1.70 A; A=1-260.
DR   PDB; 5LVS; X-ray; 1.42 A; A/B=2-260.
DR   PDB; 5SZ0; X-ray; 1.63 A; A=4-260.
DR   PDB; 5SZ1; X-ray; 1.55 A; A=4-260.
DR   PDB; 5SZ2; X-ray; 1.63 A; A=4-260.
DR   PDB; 5SZ3; X-ray; 1.69 A; A=4-260.
DR   PDB; 5SZ4; X-ray; 1.60 A; A=4-260.
DR   PDB; 5SZ5; X-ray; 1.27 A; A=4-260.
DR   PDB; 5SZ6; X-ray; 1.15 A; A=4-260.
DR   PDB; 5SZ7; X-ray; 1.78 A; A=4-260.
DR   PDB; 6CA2; X-ray; 2.50 A; A=1-260.
DR   PDB; 7CA2; X-ray; 2.40 A; A=1-260.
DR   PDB; 8CA2; X-ray; 2.40 A; A=1-260.
DR   PDB; 9CA2; X-ray; 2.80 A; A=1-260.
DR   PDBsum; 12CA; -.
DR   PDBsum; 1A42; -.
DR   PDBsum; 1AM6; -.
DR   PDBsum; 1AVN; -.
DR   PDBsum; 1BCD; -.
DR   PDBsum; 1BIC; -.
DR   PDBsum; 1BN1; -.
DR   PDBsum; 1BN3; -.
DR   PDBsum; 1BN4; -.
DR   PDBsum; 1BNM; -.
DR   PDBsum; 1BNN; -.
DR   PDBsum; 1BNQ; -.
DR   PDBsum; 1BNT; -.
DR   PDBsum; 1BNU; -.
DR   PDBsum; 1BNV; -.
DR   PDBsum; 1BNW; -.
DR   PDBsum; 1BV3; -.
DR   PDBsum; 1CA2; -.
DR   PDBsum; 1CA3; -.
DR   PDBsum; 1CAH; -.
DR   PDBsum; 1CAI; -.
DR   PDBsum; 1CAJ; -.
DR   PDBsum; 1CAK; -.
DR   PDBsum; 1CAL; -.
DR   PDBsum; 1CAM; -.
DR   PDBsum; 1CAN; -.
DR   PDBsum; 1CAO; -.
DR   PDBsum; 1CAY; -.
DR   PDBsum; 1CAZ; -.
DR   PDBsum; 1CCS; -.
DR   PDBsum; 1CCT; -.
DR   PDBsum; 1CCU; -.
DR   PDBsum; 1CIL; -.
DR   PDBsum; 1CIM; -.
DR   PDBsum; 1CIN; -.
DR   PDBsum; 1CNB; -.
DR   PDBsum; 1CNC; -.
DR   PDBsum; 1CNG; -.
DR   PDBsum; 1CNH; -.
DR   PDBsum; 1CNI; -.
DR   PDBsum; 1CNJ; -.
DR   PDBsum; 1CNK; -.
DR   PDBsum; 1CNW; -.
DR   PDBsum; 1CNX; -.
DR   PDBsum; 1CNY; -.
DR   PDBsum; 1CRA; -.
DR   PDBsum; 1CVA; -.
DR   PDBsum; 1CVB; -.
DR   PDBsum; 1CVC; -.
DR   PDBsum; 1CVD; -.
DR   PDBsum; 1CVE; -.
DR   PDBsum; 1CVF; -.
DR   PDBsum; 1CVH; -.
DR   PDBsum; 1DCA; -.
DR   PDBsum; 1DCB; -.
DR   PDBsum; 1EOU; -.
DR   PDBsum; 1F2W; -.
DR   PDBsum; 1FQL; -.
DR   PDBsum; 1FQM; -.
DR   PDBsum; 1FQN; -.
DR   PDBsum; 1FQR; -.
DR   PDBsum; 1FR4; -.
DR   PDBsum; 1FR7; -.
DR   PDBsum; 1FSN; -.
DR   PDBsum; 1FSQ; -.
DR   PDBsum; 1FSR; -.
DR   PDBsum; 1G0E; -.
DR   PDBsum; 1G0F; -.
DR   PDBsum; 1G1D; -.
DR   PDBsum; 1G3Z; -.
DR   PDBsum; 1G45; -.
DR   PDBsum; 1G46; -.
DR   PDBsum; 1G48; -.
DR   PDBsum; 1G4J; -.
DR   PDBsum; 1G4O; -.
DR   PDBsum; 1G52; -.
DR   PDBsum; 1G53; -.
DR   PDBsum; 1G54; -.
DR   PDBsum; 1H4N; -.
DR   PDBsum; 1H9N; -.
DR   PDBsum; 1H9Q; -.
DR   PDBsum; 1HCA; -.
DR   PDBsum; 1HEA; -.
DR   PDBsum; 1HEB; -.
DR   PDBsum; 1HEC; -.
DR   PDBsum; 1HED; -.
DR   PDBsum; 1HVA; -.
DR   PDBsum; 1I8Z; -.
DR   PDBsum; 1I90; -.
DR   PDBsum; 1I91; -.
DR   PDBsum; 1I9L; -.
DR   PDBsum; 1I9M; -.
DR   PDBsum; 1I9N; -.
DR   PDBsum; 1I9O; -.
DR   PDBsum; 1I9P; -.
DR   PDBsum; 1I9Q; -.
DR   PDBsum; 1IF4; -.
DR   PDBsum; 1IF5; -.
DR   PDBsum; 1IF6; -.
DR   PDBsum; 1IF7; -.
DR   PDBsum; 1IF8; -.
DR   PDBsum; 1IF9; -.
DR   PDBsum; 1KWQ; -.
DR   PDBsum; 1KWR; -.
DR   PDBsum; 1LG5; -.
DR   PDBsum; 1LG6; -.
DR   PDBsum; 1LGD; -.
DR   PDBsum; 1LUG; -.
DR   PDBsum; 1LZV; -.
DR   PDBsum; 1MOO; -.
DR   PDBsum; 1MUA; -.
DR   PDBsum; 1OKL; -.
DR   PDBsum; 1OKM; -.
DR   PDBsum; 1OKN; -.
DR   PDBsum; 1OQ5; -.
DR   PDBsum; 1RAY; -.
DR   PDBsum; 1RAZ; -.
DR   PDBsum; 1RZA; -.
DR   PDBsum; 1RZB; -.
DR   PDBsum; 1RZC; -.
DR   PDBsum; 1RZD; -.
DR   PDBsum; 1RZE; -.
DR   PDBsum; 1T9N; -.
DR   PDBsum; 1TB0; -.
DR   PDBsum; 1TBT; -.
DR   PDBsum; 1TE3; -.
DR   PDBsum; 1TEQ; -.
DR   PDBsum; 1TEU; -.
DR   PDBsum; 1TG3; -.
DR   PDBsum; 1TG9; -.
DR   PDBsum; 1TH9; -.
DR   PDBsum; 1THK; -.
DR   PDBsum; 1TTM; -.
DR   PDBsum; 1UGA; -.
DR   PDBsum; 1UGB; -.
DR   PDBsum; 1UGC; -.
DR   PDBsum; 1UGD; -.
DR   PDBsum; 1UGE; -.
DR   PDBsum; 1UGF; -.
DR   PDBsum; 1UGG; -.
DR   PDBsum; 1XEG; -.
DR   PDBsum; 1XEV; -.
DR   PDBsum; 1XPZ; -.
DR   PDBsum; 1XQ0; -.
DR   PDBsum; 1YDA; -.
DR   PDBsum; 1YDB; -.
DR   PDBsum; 1YDC; -.
DR   PDBsum; 1YDD; -.
DR   PDBsum; 1YO0; -.
DR   PDBsum; 1YO1; -.
DR   PDBsum; 1YO2; -.
DR   PDBsum; 1Z9Y; -.
DR   PDBsum; 1ZE8; -.
DR   PDBsum; 1ZFK; -.
DR   PDBsum; 1ZFQ; -.
DR   PDBsum; 1ZGE; -.
DR   PDBsum; 1ZGF; -.
DR   PDBsum; 1ZH9; -.
DR   PDBsum; 1ZSA; -.
DR   PDBsum; 1ZSB; -.
DR   PDBsum; 1ZSC; -.
DR   PDBsum; 2ABE; -.
DR   PDBsum; 2AW1; -.
DR   PDBsum; 2AX2; -.
DR   PDBsum; 2CA2; -.
DR   PDBsum; 2CBA; -.
DR   PDBsum; 2CBB; -.
DR   PDBsum; 2CBC; -.
DR   PDBsum; 2CBD; -.
DR   PDBsum; 2CBE; -.
DR   PDBsum; 2EU2; -.
DR   PDBsum; 2EU3; -.
DR   PDBsum; 2EZ7; -.
DR   PDBsum; 2F14; -.
DR   PDBsum; 2FMG; -.
DR   PDBsum; 2FMZ; -.
DR   PDBsum; 2FNK; -.
DR   PDBsum; 2FNM; -.
DR   PDBsum; 2FNN; -.
DR   PDBsum; 2FOQ; -.
DR   PDBsum; 2FOS; -.
DR   PDBsum; 2FOU; -.
DR   PDBsum; 2FOV; -.
DR   PDBsum; 2GD8; -.
DR   PDBsum; 2GEH; -.
DR   PDBsum; 2H15; -.
DR   PDBsum; 2H4N; -.
DR   PDBsum; 2HD6; -.
DR   PDBsum; 2HKK; -.
DR   PDBsum; 2HL4; -.
DR   PDBsum; 2HNC; -.
DR   PDBsum; 2HOC; -.
DR   PDBsum; 2ILI; -.
DR   PDBsum; 2NNG; -.
DR   PDBsum; 2NNO; -.
DR   PDBsum; 2NNS; -.
DR   PDBsum; 2NNV; -.
DR   PDBsum; 2NWO; -.
DR   PDBsum; 2NWP; -.
DR   PDBsum; 2NWY; -.
DR   PDBsum; 2NWZ; -.
DR   PDBsum; 2NXR; -.
DR   PDBsum; 2NXS; -.
DR   PDBsum; 2NXT; -.
DR   PDBsum; 2O4Z; -.
DR   PDBsum; 2OSF; -.
DR   PDBsum; 2OSM; -.
DR   PDBsum; 2POU; -.
DR   PDBsum; 2POV; -.
DR   PDBsum; 2POW; -.
DR   PDBsum; 2Q1B; -.
DR   PDBsum; 2Q1Q; -.
DR   PDBsum; 2Q38; -.
DR   PDBsum; 2QO8; -.
DR   PDBsum; 2QOA; -.
DR   PDBsum; 2QP6; -.
DR   PDBsum; 2VVA; -.
DR   PDBsum; 2VVB; -.
DR   PDBsum; 2WD2; -.
DR   PDBsum; 2WD3; -.
DR   PDBsum; 2WEG; -.
DR   PDBsum; 2WEH; -.
DR   PDBsum; 2WEJ; -.
DR   PDBsum; 2WEO; -.
DR   PDBsum; 2X7S; -.
DR   PDBsum; 2X7T; -.
DR   PDBsum; 2X7U; -.
DR   PDBsum; 3B4F; -.
DR   PDBsum; 3BET; -.
DR   PDBsum; 3BL0; -.
DR   PDBsum; 3BL1; -.
DR   PDBsum; 3C7P; -.
DR   PDBsum; 3CA2; -.
DR   PDBsum; 3CAJ; -.
DR   PDBsum; 3CYU; -.
DR   PDBsum; 3D8W; -.
DR   PDBsum; 3D92; -.
DR   PDBsum; 3D93; -.
DR   PDBsum; 3D9Z; -.
DR   PDBsum; 3DAZ; -.
DR   PDBsum; 3DBU; -.
DR   PDBsum; 3DC3; -.
DR   PDBsum; 3DC9; -.
DR   PDBsum; 3DCC; -.
DR   PDBsum; 3DCS; -.
DR   PDBsum; 3DCW; -.
DR   PDBsum; 3DD0; -.
DR   PDBsum; 3DD8; -.
DR   PDBsum; 3DV7; -.
DR   PDBsum; 3DVB; -.
DR   PDBsum; 3DVC; -.
DR   PDBsum; 3DVD; -.
DR   PDBsum; 3EFI; -.
DR   PDBsum; 3EFT; -.
DR   PDBsum; 3F4X; -.
DR   PDBsum; 3F8E; -.
DR   PDBsum; 3FFP; -.
DR   PDBsum; 3GZ0; -.
DR   PDBsum; 3HFP; -.
DR   PDBsum; 3HKN; -.
DR   PDBsum; 3HKQ; -.
DR   PDBsum; 3HKT; -.
DR   PDBsum; 3HKU; -.
DR   PDBsum; 3HLJ; -.
DR   PDBsum; 3HS4; -.
DR   PDBsum; 3IBI; -.
DR   PDBsum; 3IBL; -.
DR   PDBsum; 3IBN; -.
DR   PDBsum; 3IBU; -.
DR   PDBsum; 3IEO; -.
DR   PDBsum; 3IGP; -.
DR   PDBsum; 3K2F; -.
DR   PDBsum; 3K34; -.
DR   PDBsum; 3K7K; -.
DR   PDBsum; 3KIG; -.
DR   PDBsum; 3KKX; -.
DR   PDBsum; 3KNE; -.
DR   PDBsum; 3KOI; -.
DR   PDBsum; 3KOK; -.
DR   PDBsum; 3KON; -.
DR   PDBsum; 3KS3; -.
DR   PDBsum; 3KWA; -.
DR   PDBsum; 3L14; -.
DR   PDBsum; 3M04; -.
DR   PDBsum; 3M14; -.
DR   PDBsum; 3M1J; -.
DR   PDBsum; 3M1K; -.
DR   PDBsum; 3M1Q; -.
DR   PDBsum; 3M1W; -.
DR   PDBsum; 3M2N; -.
DR   PDBsum; 3M2X; -.
DR   PDBsum; 3M2Y; -.
DR   PDBsum; 3M2Z; -.
DR   PDBsum; 3M3X; -.
DR   PDBsum; 3M40; -.
DR   PDBsum; 3M5E; -.
DR   PDBsum; 3M5S; -.
DR   PDBsum; 3M5T; -.
DR   PDBsum; 3M67; -.
DR   PDBsum; 3M96; -.
DR   PDBsum; 3M98; -.
DR   PDBsum; 3MHC; -.
DR   PDBsum; 3MHI; -.
DR   PDBsum; 3MHL; -.
DR   PDBsum; 3MHM; -.
DR   PDBsum; 3MHO; -.
DR   PDBsum; 3ML2; -.
DR   PDBsum; 3MMF; -.
DR   PDBsum; 3MNA; -.
DR   PDBsum; 3MNH; -.
DR   PDBsum; 3MNI; -.
DR   PDBsum; 3MNJ; -.
DR   PDBsum; 3MNK; -.
DR   PDBsum; 3MNU; -.
DR   PDBsum; 3MWO; -.
DR   PDBsum; 3MYQ; -.
DR   PDBsum; 3MZC; -.
DR   PDBsum; 3N0N; -.
DR   PDBsum; 3N2P; -.
DR   PDBsum; 3N3J; -.
DR   PDBsum; 3N4B; -.
DR   PDBsum; 3NB5; -.
DR   PDBsum; 3NI5; -.
DR   PDBsum; 3NJ9; -.
DR   PDBsum; 3OIK; -.
DR   PDBsum; 3OIL; -.
DR   PDBsum; 3OIM; -.
DR   PDBsum; 3OKU; -.
DR   PDBsum; 3OKV; -.
DR   PDBsum; 3OY0; -.
DR   PDBsum; 3OYQ; -.
DR   PDBsum; 3OYS; -.
DR   PDBsum; 3P3H; -.
DR   PDBsum; 3P3J; -.
DR   PDBsum; 3P44; -.
DR   PDBsum; 3P4V; -.
DR   PDBsum; 3P55; -.
DR   PDBsum; 3P58; -.
DR   PDBsum; 3P5A; -.
DR   PDBsum; 3P5L; -.
DR   PDBsum; 3PJJ; -.
DR   PDBsum; 3PO6; -.
DR   PDBsum; 3PYK; -.
DR   PDBsum; 3QYK; -.
DR   PDBsum; 3R16; -.
DR   PDBsum; 3R17; -.
DR   PDBsum; 3RG3; -.
DR   PDBsum; 3RG4; -.
DR   PDBsum; 3RGE; -.
DR   PDBsum; 3RJ7; -.
DR   PDBsum; 3RLD; -.
DR   PDBsum; 3RYJ; -.
DR   PDBsum; 3RYV; -.
DR   PDBsum; 3RYX; -.
DR   PDBsum; 3RYY; -.
DR   PDBsum; 3RYZ; -.
DR   PDBsum; 3RZ0; -.
DR   PDBsum; 3RZ1; -.
DR   PDBsum; 3RZ5; -.
DR   PDBsum; 3RZ7; -.
DR   PDBsum; 3RZ8; -.
DR   PDBsum; 3S71; -.
DR   PDBsum; 3S72; -.
DR   PDBsum; 3S73; -.
DR   PDBsum; 3S74; -.
DR   PDBsum; 3S75; -.
DR   PDBsum; 3S76; -.
DR   PDBsum; 3S77; -.
DR   PDBsum; 3S78; -.
DR   PDBsum; 3S8X; -.
DR   PDBsum; 3S9T; -.
DR   PDBsum; 3SAP; -.
DR   PDBsum; 3SAX; -.
DR   PDBsum; 3SBH; -.
DR   PDBsum; 3SBI; -.
DR   PDBsum; 3T5U; -.
DR   PDBsum; 3T5Z; -.
DR   PDBsum; 3T82; -.
DR   PDBsum; 3T83; -.
DR   PDBsum; 3T84; -.
DR   PDBsum; 3T85; -.
DR   PDBsum; 3TMJ; -.
DR   PDBsum; 3TVN; -.
DR   PDBsum; 3TVO; -.
DR   PDBsum; 3U3A; -.
DR   PDBsum; 3U45; -.
DR   PDBsum; 3U47; -.
DR   PDBsum; 3U7C; -.
DR   PDBsum; 3V2J; -.
DR   PDBsum; 3V2M; -.
DR   PDBsum; 3V3F; -.
DR   PDBsum; 3V3G; -.
DR   PDBsum; 3V3H; -.
DR   PDBsum; 3V3I; -.
DR   PDBsum; 3V3J; -.
DR   PDBsum; 3V5G; -.
DR   PDBsum; 3V7X; -.
DR   PDBsum; 3VBD; -.
DR   PDBsum; 3ZP9; -.
DR   PDBsum; 4BCW; -.
DR   PDBsum; 4BF1; -.
DR   PDBsum; 4BF6; -.
DR   PDBsum; 4CA2; -.
DR   PDBsum; 4CAC; -.
DR   PDBsum; 4CQ0; -.
DR   PDBsum; 4DZ7; -.
DR   PDBsum; 4DZ9; -.
DR   PDBsum; 4E3D; -.
DR   PDBsum; 4E3F; -.
DR   PDBsum; 4E3G; -.
DR   PDBsum; 4E3H; -.
DR   PDBsum; 4E49; -.
DR   PDBsum; 4E4A; -.
DR   PDBsum; 4E5Q; -.
DR   PDBsum; 4FIK; -.
DR   PDBsum; 4FL7; -.
DR   PDBsum; 4FPT; -.
DR   PDBsum; 4FRC; -.
DR   PDBsum; 4FU5; -.
DR   PDBsum; 4FVN; -.
DR   PDBsum; 4FVO; -.
DR   PDBsum; 4G0C; -.
DR   PDBsum; 4GL1; -.
DR   PDBsum; 4HBA; -.
DR   PDBsum; 4HEW; -.
DR   PDBsum; 4HEY; -.
DR   PDBsum; 4HEZ; -.
DR   PDBsum; 4HF3; -.
DR   PDBsum; 4HT0; -.
DR   PDBsum; 4IDR; -.
DR   PDBsum; 4ILX; -.
DR   PDBsum; 4ITO; -.
DR   PDBsum; 4ITP; -.
DR   PDBsum; 4IWZ; -.
DR   PDBsum; 4JS6; -.
DR   PDBsum; 4JSA; -.
DR   PDBsum; 4JSS; -.
DR   PDBsum; 4JSW; -.
DR   PDBsum; 4JSZ; -.
DR   PDBsum; 4K0S; -.
DR   PDBsum; 4K0T; -.
DR   PDBsum; 4K0Z; -.
DR   PDBsum; 4K13; -.
DR   PDBsum; 4K1Q; -.
DR   PDBsum; 4KAP; -.
DR   PDBsum; 4KNI; -.
DR   PDBsum; 4KNJ; -.
DR   PDBsum; 4KUV; -.
DR   PDBsum; 4KUW; -.
DR   PDBsum; 4KUY; -.
DR   PDBsum; 4KV0; -.
DR   PDBsum; 4L5U; -.
DR   PDBsum; 4L5V; -.
DR   PDBsum; 4L5W; -.
DR   PDBsum; 4LHI; -.
DR   PDBsum; 4LP6; -.
DR   PDBsum; 4M2R; -.
DR   PDBsum; 4M2U; -.
DR   PDBsum; 4M2V; -.
DR   PDBsum; 4M2W; -.
DR   PDBsum; 4MDG; -.
DR   PDBsum; 4MDL; -.
DR   PDBsum; 4MDM; -.
DR   PDBsum; 4MLT; -.
DR   PDBsum; 4MLX; -.
DR   PDBsum; 4MO8; -.
DR   PDBsum; 4MTY; -.
DR   PDBsum; 4N0X; -.
DR   PDBsum; 4N16; -.
DR   PDBsum; 4PQ7; -.
DR   PDBsum; 4PXX; -.
DR   PDBsum; 4PYX; -.
DR   PDBsum; 4PYY; -.
DR   PDBsum; 4PZH; -.
DR   PDBsum; 4Q06; -.
DR   PDBsum; 4Q07; -.
DR   PDBsum; 4Q08; -.
DR   PDBsum; 4Q09; -.
DR   PDBsum; 4Q49; -.
DR   PDBsum; 4Q6D; -.
DR   PDBsum; 4Q6E; -.
DR   PDBsum; 4Q78; -.
DR   PDBsum; 4Q7P; -.
DR   PDBsum; 4Q7S; -.
DR   PDBsum; 4Q7V; -.
DR   PDBsum; 4Q7W; -.
DR   PDBsum; 4Q81; -.
DR   PDBsum; 4Q83; -.
DR   PDBsum; 4Q87; -.
DR   PDBsum; 4Q8X; -.
DR   PDBsum; 4Q8Y; -.
DR   PDBsum; 4Q8Z; -.
DR   PDBsum; 4Q90; -.
DR   PDBsum; 4Q99; -.
DR   PDBsum; 4Q9Y; -.
DR   PDBsum; 4QEF; -.
DR   PDBsum; 4QIY; -.
DR   PDBsum; 4QJM; -.
DR   PDBsum; 4QK1; -.
DR   PDBsum; 4QK2; -.
DR   PDBsum; 4QK3; -.
DR   PDBsum; 4QSA; -.
DR   PDBsum; 4QSB; -.
DR   PDBsum; 4QSI; -.
DR   PDBsum; 4QTL; -.
DR   PDBsum; 4QY3; -.
DR   PDBsum; 4R59; -.
DR   PDBsum; 4R5A; -.
DR   PDBsum; 4R5B; -.
DR   PDBsum; 4RFC; -.
DR   PDBsum; 4RFD; -.
DR   PDBsum; 4RH2; -.
DR   PDBsum; 4RIU; -.
DR   PDBsum; 4RIV; -.
DR   PDBsum; 4RN4; -.
DR   PDBsum; 4RUX; -.
DR   PDBsum; 4RUY; -.
DR   PDBsum; 4RUZ; -.
DR   PDBsum; 4WL4; -.
DR   PDBsum; 4WW6; -.
DR   PDBsum; 4XE1; -.
DR   PDBsum; 4Y0J; -.
DR   PDBsum; 4YGJ; -.
DR   PDBsum; 4YGK; -.
DR   PDBsum; 4YGL; -.
DR   PDBsum; 4YGN; -.
DR   PDBsum; 4YVY; -.
DR   PDBsum; 4YWP; -.
DR   PDBsum; 4YX4; -.
DR   PDBsum; 4YXI; -.
DR   PDBsum; 4YXO; -.
DR   PDBsum; 4YXU; -.
DR   PDBsum; 4YYT; -.
DR   PDBsum; 4Z0Q; -.
DR   PDBsum; 4Z1E; -.
DR   PDBsum; 4Z1J; -.
DR   PDBsum; 4Z1K; -.
DR   PDBsum; 4Z1N; -.
DR   PDBsum; 4ZAO; -.
DR   PDBsum; 4ZWI; -.
DR   PDBsum; 4ZWX; -.
DR   PDBsum; 4ZWY; -.
DR   PDBsum; 4ZWZ; -.
DR   PDBsum; 4ZX0; -.
DR   PDBsum; 4ZX1; -.
DR   PDBsum; 5A6H; -.
DR   PDBsum; 5AMD; -.
DR   PDBsum; 5AMG; -.
DR   PDBsum; 5AML; -.
DR   PDBsum; 5BNL; -.
DR   PDBsum; 5BRU; -.
DR   PDBsum; 5BRV; -.
DR   PDBsum; 5BRW; -.
DR   PDBsum; 5BYI; -.
DR   PDBsum; 5C8I; -.
DR   PDBsum; 5CA2; -.
DR   PDBsum; 5CAC; -.
DR   PDBsum; 5CJL; -.
DR   PDBsum; 5CLU; -.
DR   PDBsum; 5DOG; -.
DR   PDBsum; 5DOH; -.
DR   PDBsum; 5DRS; -.
DR   PDBsum; 5DSI; -.
DR   PDBsum; 5DSJ; -.
DR   PDBsum; 5DSK; -.
DR   PDBsum; 5DSL; -.
DR   PDBsum; 5DSM; -.
DR   PDBsum; 5DSN; -.
DR   PDBsum; 5DSO; -.
DR   PDBsum; 5DSP; -.
DR   PDBsum; 5DSQ; -.
DR   PDBsum; 5DSR; -.
DR   PDBsum; 5E28; -.
DR   PDBsum; 5E2K; -.
DR   PDBsum; 5E2R; -.
DR   PDBsum; 5E2S; -.
DR   PDBsum; 5EH5; -.
DR   PDBsum; 5EH7; -.
DR   PDBsum; 5EH8; -.
DR   PDBsum; 5EHE; -.
DR   PDBsum; 5EHV; -.
DR   PDBsum; 5EHW; -.
DR   PDBsum; 5EIJ; -.
DR   PDBsum; 5EKH; -.
DR   PDBsum; 5EKJ; -.
DR   PDBsum; 5EKM; -.
DR   PDBsum; 5EOI; -.
DR   PDBsum; 5FDC; -.
DR   PDBsum; 5FDI; -.
DR   PDBsum; 5FLO; -.
DR   PDBsum; 5FLP; -.
DR   PDBsum; 5FLQ; -.
DR   PDBsum; 5FLR; -.
DR   PDBsum; 5FLS; -.
DR   PDBsum; 5FLT; -.
DR   PDBsum; 5FNG; -.
DR   PDBsum; 5FNH; -.
DR   PDBsum; 5FNI; -.
DR   PDBsum; 5FNJ; -.
DR   PDBsum; 5FNK; -.
DR   PDBsum; 5FNL; -.
DR   PDBsum; 5FNM; -.
DR   PDBsum; 5G01; -.
DR   PDBsum; 5G03; -.
DR   PDBsum; 5G0B; -.
DR   PDBsum; 5G0C; -.
DR   PDBsum; 5J8Z; -.
DR   PDBsum; 5JDV; -.
DR   PDBsum; 5JE7; -.
DR   PDBsum; 5JEG; -.
DR   PDBsum; 5JEH; -.
DR   PDBsum; 5JEP; -.
DR   PDBsum; 5JES; -.
DR   PDBsum; 5JG3; -.
DR   PDBsum; 5JG5; -.
DR   PDBsum; 5JGS; -.
DR   PDBsum; 5JGT; -.
DR   PDBsum; 5JQ0; -.
DR   PDBsum; 5JQT; -.
DR   PDBsum; 5L3O; -.
DR   PDBsum; 5L6K; -.
DR   PDBsum; 5LMD; -.
DR   PDBsum; 5LVS; -.
DR   PDBsum; 5SZ0; -.
DR   PDBsum; 5SZ1; -.
DR   PDBsum; 5SZ2; -.
DR   PDBsum; 5SZ3; -.
DR   PDBsum; 5SZ4; -.
DR   PDBsum; 5SZ5; -.
DR   PDBsum; 5SZ6; -.
DR   PDBsum; 5SZ7; -.
DR   PDBsum; 6CA2; -.
DR   PDBsum; 7CA2; -.
DR   PDBsum; 8CA2; -.
DR   PDBsum; 9CA2; -.
DR   ProteinModelPortal; P00918; -.
DR   SMR; P00918; -.
DR   BioGrid; 107215; 14.
DR   IntAct; P00918; 6.
DR   MINT; MINT-1367766; -.
DR   STRING; 9606.ENSP00000285379; -.
DR   BindingDB; P00918; -.
DR   ChEMBL; CHEMBL205; -.
DR   DrugBank; DB03333; (4-sulfamoyl-phenyl)-thiocarbamic acid O-(2-thiophen-3-yl-ethyl) ester.
DR   DrugBank; DB02479; (R)-N-(3-Indol-1-Yl-2-Methyl-Propyl)-4-Sulfamoyl-Benzamide.
DR   DrugBank; DB03950; (S)-N-(3-Indol-1-Yl-2-Methyl-Propyl)-4-Sulfamoyl-Benzamide.
DR   DrugBank; DB08659; 2-(hydrazinocarbonyl)-3-phenyl-1H-indole-5-sulfonamide.
DR   DrugBank; DB08046; 2-chloro-5-[(1S)-1-hydroxy-3-oxo-2H-isoindol-1-yl]benzenesulfonamide.
DR   DrugBank; DB08156; 3-[4-(AMINOSULFONYL)PHENYL]PROPANOIC ACID.
DR   DrugBank; DB04203; 3-Mercuri-4-Aminobenzenesulfonamide.
DR   DrugBank; DB04394; 3-Nitro-4-(2-Oxo-Pyrrolidin-1-Yl)-Benzenesulfonamide.
DR   DrugBank; DB08782; 4-(2-AMINOETHYL)BENZENESULFONAMIDE.
DR   DrugBank; DB02429; 4-(Aminosulfonyl)-N-[(4-Fluorophenyl)Methyl]-Benzamide.
DR   DrugBank; DB01671; 4-(Hydroxymercury)Benzoic Acid.
DR   DrugBank; DB08202; 4-({[(4-METHYLPIPERAZIN-1-YL)AMINO]CARBONOTHIOYL}AMINO)BENZENESULFONAMIDE.
DR   DrugBank; DB01784; 4-Flourobenzenesulfonamide.
DR   DrugBank; DB03385; 4-Methylimidazole.
DR   DrugBank; DB03697; 4-Sulfonamide-[1-(4-Aminobutane)]Benzamide.
DR   DrugBank; DB04002; 4-Sulfonamide-[4-(Thiomethylaminobutane)]Benzamide.
DR   DrugBank; DB00819; Acetazolamide.
DR   DrugBank; DB03877; AL4623.
DR   DrugBank; DB04089; AL5300.
DR   DrugBank; DB01964; AL5424.
DR   DrugBank; DB03526; AL5927.
DR   DrugBank; DB04371; AL6528.
DR   DrugBank; DB02220; Al7089a.
DR   DrugBank; DB03221; AL7099A.
DR   DrugBank; DB02602; AL7182.
DR   DrugBank; DB02535; Aminodi(Ethyloxy)Ethylaminocarbonylbenzenesulfonamide.
DR   DrugBank; DB00436; Bendroflumethiazide.
DR   DrugBank; DB00562; Benzthiazide.
DR   DrugBank; DB01194; Brinzolamide.
DR   DrugBank; DB00880; Chlorothiazide.
DR   DrugBank; DB02679; Cyanamide.
DR   DrugBank; DB00606; Cyclothiazide.
DR   DrugBank; DB02866; Dansylamide.
DR   DrugBank; DB01119; Diazoxide.
DR   DrugBank; DB01144; Diclofenamide.
DR   DrugBank; DB00869; Dorzolamide.
DR   DrugBank; DB08846; Ellagic Acid.
DR   DrugBank; DB01031; Ethinamate.
DR   DrugBank; DB00311; Ethoxzolamide.
DR   DrugBank; DB08157; ETHYL 3-[4-(AMINOSULFONYL)PHENYL]PROPANOATE.
DR   DrugBank; DB01942; Formic Acid.
DR   DrugBank; DB00695; Furosemide.
DR   DrugBank; DB00999; Hydrochlorothiazide.
DR   DrugBank; DB00774; Hydroflumethiazide.
DR   DrugBank; DB08165; indane-5-sulfonamide.
DR   DrugBank; DB03975; Mercuribenzoic Acid.
DR   DrugBank; DB00703; Methazolamide.
DR   DrugBank; DB00232; Methyclothiazide.
DR   DrugBank; DB02069; N-(2-Flouro-Benzyl)-4-Sulfamoyl-Benzamide.
DR   DrugBank; DB08301; N-({[4-(AMINOSULFONYL)PHENYL]AMINO}CARBONYL)-4-METHYLBENZENESULFONAMIDE.
DR   DrugBank; DB03596; N-[2-(1h-Indol-5-Yl)-Butyl]-4-Sulfamoyl-Benzamide.
DR   DrugBank; DB07476; N-[4-(AMINOSULFONYL)PHENYL]-2-MERCAPTOBENZAMIDE.
DR   DrugBank; DB01748; N-Benzyl-4-Sulfamoyl-Benzamide.
DR   DrugBank; DB08155; N-{2-[4-(AMINOSULFONYL)PHENYL]ETHYL}ACETAMIDE.
DR   DrugBank; DB07710; PHENYLALANYLAMINODI(ETHYLOXY)ETHYL BENZENESULFONAMIDEAMINOCARBONYLBENZENESULFONAMIDE.
DR   DrugBank; DB01325; Quinethazone.
DR   DrugBank; DB08329; SULTHIAME.
DR   DrugBank; DB00273; Topiramate.
DR   DrugBank; DB01021; Trichlormethiazide.
DR   DrugBank; DB03904; Urea.
DR   DrugBank; DB00909; Zonisamide.
DR   iPTMnet; P00918; -.
DR   PhosphoSitePlus; P00918; -.
DR   BioMuta; CA2; -.
DR   OGP; P00918; -.
DR   REPRODUCTION-2DPAGE; IPI00218414; -.
DR   REPRODUCTION-2DPAGE; P00918; -.
DR   UCD-2DPAGE; P00918; -.
DR   EPD; P00918; -.
DR   PaxDb; P00918; -.
DR   PeptideAtlas; P00918; -.
DR   PRIDE; P00918; -.
DR   DNASU; 760; -.
DR   Ensembl; ENST00000285379; ENSP00000285379; ENSG00000104267.
DR   GeneID; 760; -.
DR   KEGG; hsa:760; -.
DR   CTD; 760; -.
DR   DisGeNET; 760; -.
DR   GeneCards; CA2; -.
DR   HGNC; HGNC:1373; CA2.
DR   HPA; CAB010102; -.
DR   HPA; HPA001550; -.
DR   MalaCards; CA2; -.
DR   MIM; 259730; phenotype.
DR   MIM; 611492; gene.
DR   neXtProt; NX_P00918; -.
DR   OpenTargets; ENSG00000104267; -.
DR   Orphanet; 2785; Osteopetrosis with renal tubular acidosis.
DR   PharmGKB; PA25989; -.
DR   eggNOG; KOG0382; Eukaryota.
DR   eggNOG; COG3338; LUCA.
DR   GeneTree; ENSGT00760000118915; -.
DR   HOGENOM; HOG000112637; -.
DR   HOVERGEN; HBG002837; -.
DR   InParanoid; P00918; -.
DR   KO; K18245; -.
DR   OMA; AHHWGYG; -.
DR   OrthoDB; EOG091G0XFM; -.
DR   PhylomeDB; P00918; -.
DR   TreeFam; TF316425; -.
DR   BRENDA; 4.2.1.1; 2681.
DR   Reactome; R-HSA-1237044; Erythrocytes take up carbon dioxide and release oxygen.
DR   Reactome; R-HSA-1247673; Erythrocytes take up oxygen and release carbon dioxide.
DR   Reactome; R-HSA-1475029; Reversible hydration of carbon dioxide.
DR   SABIO-RK; P00918; -.
DR   ChiTaRS; CA2; human.
DR   EvolutionaryTrace; P00918; -.
DR   GeneWiki; Carbonic_anhydrase_II; -.
DR   GenomeRNAi; 760; -.
DR   PRO; PR:P00918; -.
DR   Proteomes; UP000005640; Chromosome 8.
DR   Bgee; ENSG00000104267; -.
DR   CleanEx; HS_CA2; -.
DR   ExpressionAtlas; P00918; baseline and differential.
DR   Genevisible; P00918; HS.
DR   GO; GO:0045177; C:apical part of cell; IDA:UniProtKB.
DR   GO; GO:0030424; C:axon; IEA:Ensembl.
DR   GO; GO:0016323; C:basolateral plasma membrane; IEA:Ensembl.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0070062; C:extracellular exosome; IDA:UniProtKB.
DR   GO; GO:0005615; C:extracellular space; IEA:Ensembl.
DR   GO; GO:0005902; C:microvillus; IEA:Ensembl.
DR   GO; GO:0043209; C:myelin sheath; IEA:Ensembl.
DR   GO; GO:0005886; C:plasma membrane; IDA:UniProtKB.
DR   GO; GO:0004064; F:arylesterase activity; IMP:CACAO.
DR   GO; GO:0004089; F:carbonate dehydratase activity; IMP:CACAO.
DR   GO; GO:0008270; F:zinc ion binding; IDA:UniProtKB.
DR   GO; GO:0038166; P:angiotensin-activated signaling pathway; IDA:UniProtKB.
DR   GO; GO:0015701; P:bicarbonate transport; TAS:Reactome.
DR   GO; GO:0015670; P:carbon dioxide transport; IEA:Ensembl.
DR   GO; GO:0071498; P:cellular response to fluid shear stress; IEA:Ensembl.
DR   GO; GO:0001822; P:kidney development; IEA:Ensembl.
DR   GO; GO:0002009; P:morphogenesis of an epithelium; IEA:Ensembl.
DR   GO; GO:0042475; P:odontogenesis of dentin-containing tooth; IEA:Ensembl.
DR   GO; GO:0006730; P:one-carbon metabolic process; IEA:InterPro.
DR   GO; GO:0045780; P:positive regulation of bone resorption; IEA:Ensembl.
DR   GO; GO:0032849; P:positive regulation of cellular pH reduction; IEA:Ensembl.
DR   GO; GO:2001150; P:positive regulation of dipeptide transmembrane transport; ISS:UniProtKB.
DR   GO; GO:0045672; P:positive regulation of osteoclast differentiation; IEA:Ensembl.
DR   GO; GO:0032230; P:positive regulation of synaptic transmission, GABAergic; IEA:Ensembl.
DR   GO; GO:0044070; P:regulation of anion transport; IDA:UniProtKB.
DR   GO; GO:2001225; P:regulation of chloride transport; IEA:Ensembl.
DR   GO; GO:0051453; P:regulation of intracellular pH; ISS:UniProtKB.
DR   GO; GO:0043627; P:response to estrogen; IEA:Ensembl.
DR   GO; GO:0009268; P:response to pH; IEA:Ensembl.
DR   GO; GO:0048545; P:response to steroid hormone; IEA:Ensembl.
DR   GO; GO:0010043; P:response to zinc ion; IEA:Ensembl.
DR   GO; GO:0046903; P:secretion; IEA:Ensembl.
DR   Gene3D; 3.10.200.10; -; 1.
DR   InterPro; IPR001148; Carbonic_anhydrase_a.
DR   InterPro; IPR023561; Carbonic_anhydrase_a-class.
DR   InterPro; IPR018338; Carbonic_anhydrase_a-class_CS.
DR   PANTHER; PTHR18952; PTHR18952; 1.
DR   Pfam; PF00194; Carb_anhydrase; 1.
DR   SMART; SM01057; Carb_anhydrase; 1.
DR   SUPFAM; SSF51069; SSF51069; 1.
DR   PROSITE; PS00162; ALPHA_CA_1; 1.
DR   PROSITE; PS51144; ALPHA_CA_2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Cell membrane; Complete proteome;
KW   Cytoplasm; Direct protein sequencing; Disease mutation; Lyase;
KW   Membrane; Metal-binding; Osteopetrosis; Phosphoprotein; Polymorphism;
KW   Reference proteome; Zinc.
FT   INIT_MET      1      1       Removed. {ECO:0000269|PubMed:4207120,
FT                                ECO:0000269|PubMed:823150}.
FT   CHAIN         2    260       Carbonic anhydrase 2.
FT                                /FTId=PRO_0000077418.
FT   DOMAIN        3    259       Alpha-carbonic anhydrase.
FT                                {ECO:0000255|PROSITE-ProRule:PRU01134}.
FT   REGION      198    199       Substrate binding.
FT                                {ECO:0000269|PubMed:10550681,
FT                                ECO:0000269|PubMed:19520834}.
FT   ACT_SITE     64     64       Proton acceptor.
FT                                {ECO:0000269|PubMed:15667203,
FT                                ECO:0000269|PubMed:17330962,
FT                                ECO:0000269|PubMed:19170619}.
FT   ACT_SITE     67     67       {ECO:0000269|PubMed:15667203,
FT                                ECO:0000269|PubMed:17330962,
FT                                ECO:0000269|PubMed:19170619}.
FT   ACT_SITE    127    127       {ECO:0000269|PubMed:15667203,
FT                                ECO:0000269|PubMed:17330962,
FT                                ECO:0000269|PubMed:19170619}.
FT   METAL        94     94       Zinc; catalytic.
FT                                {ECO:0000269|PubMed:11076507,
FT                                ECO:0000269|PubMed:12499545,
FT                                ECO:0000269|PubMed:1336460,
FT                                ECO:0000269|PubMed:1433293,
FT                                ECO:0000269|PubMed:1909891,
FT                                ECO:0000269|PubMed:19583303,
FT                                ECO:0000269|PubMed:3151019,
FT                                ECO:0000269|PubMed:3151020,
FT                                ECO:0000269|PubMed:4621826,
FT                                ECO:0000269|PubMed:7761440,
FT                                ECO:0000269|PubMed:7803386,
FT                                ECO:0000269|PubMed:7901850,
FT                                ECO:0000269|PubMed:8218160,
FT                                ECO:0000269|PubMed:8262987,
FT                                ECO:0000269|PubMed:8331673,
FT                                ECO:0000269|PubMed:8399159,
FT                                ECO:0000269|PubMed:8431430,
FT                                ECO:0000269|PubMed:8451242,
FT                                ECO:0000269|PubMed:8482389,
FT                                ECO:0000269|PubMed:8639494,
FT                                ECO:0000269|PubMed:8987974,
FT                                ECO:0000269|PubMed:9398308,
FT                                ECO:0000269|PubMed:9865942}.
FT   METAL        96     96       Zinc; catalytic.
FT                                {ECO:0000269|PubMed:11076507,
FT                                ECO:0000269|PubMed:12499545,
FT                                ECO:0000269|PubMed:1336460,
FT                                ECO:0000269|PubMed:1433293,
FT                                ECO:0000269|PubMed:1909891,
FT                                ECO:0000269|PubMed:19583303,
FT                                ECO:0000269|PubMed:3151019,
FT                                ECO:0000269|PubMed:3151020,
FT                                ECO:0000269|PubMed:7761440,
FT                                ECO:0000269|PubMed:7803386,
FT                                ECO:0000269|PubMed:7901850,
FT                                ECO:0000269|PubMed:8218160,
FT                                ECO:0000269|PubMed:8262987,
FT                                ECO:0000269|PubMed:8331673,
FT                                ECO:0000269|PubMed:8399159,
FT                                ECO:0000269|PubMed:8431430,
FT                                ECO:0000269|PubMed:8451242,
FT                                ECO:0000269|PubMed:8482389,
FT                                ECO:0000269|PubMed:8639494,
FT                                ECO:0000269|PubMed:8987974,
FT                                ECO:0000269|PubMed:9398308,
FT                                ECO:0000269|PubMed:9865942}.
FT   METAL       119    119       Zinc; catalytic.
FT                                {ECO:0000269|PubMed:11076507,
FT                                ECO:0000269|PubMed:12499545,
FT                                ECO:0000269|PubMed:1336460,
FT                                ECO:0000269|PubMed:1433293,
FT                                ECO:0000269|PubMed:1909891,
FT                                ECO:0000269|PubMed:19583303,
FT                                ECO:0000269|PubMed:3151019,
FT                                ECO:0000269|PubMed:3151020,
FT                                ECO:0000269|PubMed:7761440,
FT                                ECO:0000269|PubMed:7803386,
FT                                ECO:0000269|PubMed:7901850,
FT                                ECO:0000269|PubMed:8218160,
FT                                ECO:0000269|PubMed:8262987,
FT                                ECO:0000269|PubMed:8331673,
FT                                ECO:0000269|PubMed:8399159,
FT                                ECO:0000269|PubMed:8431430,
FT                                ECO:0000269|PubMed:8451242,
FT                                ECO:0000269|PubMed:8482389,
FT                                ECO:0000269|PubMed:8639494,
FT                                ECO:0000269|PubMed:8987974,
FT                                ECO:0000269|PubMed:9398308,
FT                                ECO:0000269|PubMed:9865942}.
FT   BINDING      62     62       Activator. {ECO:0000269|PubMed:16214338,
FT                                ECO:0000269|PubMed:17127057,
FT                                ECO:0000269|PubMed:9265618}.
FT   BINDING      67     67       Activator. {ECO:0000269|PubMed:16214338,
FT                                ECO:0000269|PubMed:17127057,
FT                                ECO:0000269|PubMed:9265618}.
FT   BINDING      92     92       Activator. {ECO:0000269|PubMed:16214338,
FT                                ECO:0000269|PubMed:17127057,
FT                                ECO:0000269|PubMed:9265618}.
FT   MOD_RES       2      2       N-acetylserine.
FT                                {ECO:0000269|PubMed:4207120,
FT                                ECO:0000269|PubMed:823150}.
FT   MOD_RES       2      2       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:P27139}.
FT   MOD_RES     165    165       Phosphoserine.
FT                                {ECO:0000244|PubMed:24275569}.
FT   MOD_RES     172    172       Phosphoserine.
FT                                {ECO:0000244|PubMed:24275569}.
FT   VARIANT      18     18       K -> E (in Jogjakarta;
FT                                dbSNP:rs118203931).
FT                                {ECO:0000269|PubMed:6817747}.
FT                                /FTId=VAR_001380.
FT   VARIANT      92     92       Q -> P (in OPTB3; in Czechoslovakia).
FT                                {ECO:0000269|PubMed:15300855,
FT                                ECO:0000269|PubMed:9143915}.
FT                                /FTId=VAR_001381.
FT   VARIANT      94     94       H -> Y (in OPTB3; partial loss of
FT                                activity). {ECO:0000269|PubMed:15300855}.
FT                                /FTId=VAR_021009.
FT   VARIANT     107    107       H -> Y (in OPTB3; frequent mutation;
FT                                dbSNP:rs118203933).
FT                                {ECO:0000269|PubMed:15300855,
FT                                ECO:0000269|PubMed:1542674,
FT                                ECO:0000269|PubMed:1928091,
FT                                ECO:0000269|PubMed:8834238}.
FT                                /FTId=VAR_001382.
FT   VARIANT     144    144       G -> R (in OPTB3; complete loss of
FT                                activity). {ECO:0000269|PubMed:15300855}.
FT                                /FTId=VAR_021010.
FT   VARIANT     236    236       P -> H (in Melbourne; dbSNP:rs118203932).
FT                                {ECO:0000269|PubMed:6407977}.
FT                                /FTId=VAR_001383.
FT   VARIANT     252    252       N -> D (in dbSNP:rs2228063).
FT                                /FTId=VAR_001384.
FT   MUTAGEN       5      5       W->A: Impaired activity, not rescued by
FT                                4-methylimidazole (4-MI); when associated
FT                                with W-64. {ECO:0000269|PubMed:17071654}.
FT   MUTAGEN       7      7       Y->F: Enhanced activity.
FT                                {ECO:0000269|PubMed:12171926,
FT                                ECO:0000269|PubMed:17330962}.
FT   MUTAGEN       7      7       Y->H: Reduced proton transfer rate.
FT                                {ECO:0000269|PubMed:12171926,
FT                                ECO:0000269|PubMed:17330962}.
FT   MUTAGEN      62     62       N->A: Reduced activity.
FT                                {ECO:0000269|PubMed:15667203,
FT                                ECO:0000269|PubMed:17330962,
FT                                ECO:0000269|PubMed:18942852}.
FT   MUTAGEN      62     62       N->D: Strongly reduced activity.
FT                                {ECO:0000269|PubMed:15667203,
FT                                ECO:0000269|PubMed:17330962,
FT                                ECO:0000269|PubMed:18942852}.
FT   MUTAGEN      62     62       N->H: Reduced proton transfer; when
FT                                associated with A-64.
FT                                {ECO:0000269|PubMed:15667203,
FT                                ECO:0000269|PubMed:17330962,
FT                                ECO:0000269|PubMed:18942852}.
FT   MUTAGEN      62     62       N->L: Reduced activity.
FT                                {ECO:0000269|PubMed:15667203,
FT                                ECO:0000269|PubMed:17330962,
FT                                ECO:0000269|PubMed:18942852}.
FT   MUTAGEN      62     62       N->T: Reduced activity.
FT                                {ECO:0000269|PubMed:15667203,
FT                                ECO:0000269|PubMed:17330962,
FT                                ECO:0000269|PubMed:18942852}.
FT   MUTAGEN      62     62       N->V: Reduced activity.
FT                                {ECO:0000269|PubMed:15667203,
FT                                ECO:0000269|PubMed:17330962,
FT                                ECO:0000269|PubMed:18942852}.
FT   MUTAGEN      64     64       H->A: Reduced CO(2) hydrase activity,
FT                                rescued by 4-methylimidazole (4-MI).
FT                                Reduced proton transfer; when associated
FT                                with H-62. Enhanced proton transfer; when
FT                                associated with H-67. Enhanced proton
FT                                transfer capacity; when associated with
FT                                H-99. {ECO:0000269|PubMed:11327835,
FT                                ECO:0000269|PubMed:15667203,
FT                                ECO:0000269|PubMed:16106378,
FT                                ECO:0000269|PubMed:17071654}.
FT   MUTAGEN      64     64       H->G: Impaired activity, not rescued by
FT                                4-methylimidazole (4-MI).
FT                                {ECO:0000269|PubMed:11327835,
FT                                ECO:0000269|PubMed:15667203,
FT                                ECO:0000269|PubMed:16106378,
FT                                ECO:0000269|PubMed:17071654}.
FT   MUTAGEN      64     64       H->W: Impaired activity, rescued by 4-
FT                                methylimidazole (4-MI). Impaired
FT                                activity, not rescued by 4-
FT                                methylimidazole (4-MI); when associated
FT                                with A-5. {ECO:0000269|PubMed:11327835,
FT                                ECO:0000269|PubMed:15667203,
FT                                ECO:0000269|PubMed:16106378,
FT                                ECO:0000269|PubMed:17071654}.
FT   MUTAGEN      65     65       A->F: Reduced activity.
FT                                {ECO:0000269|PubMed:19170619}.
FT   MUTAGEN      65     65       A->H,L,S: Normal activity.
FT                                {ECO:0000269|PubMed:19170619}.
FT   MUTAGEN      67     67       N->H: Enhanced proton transfer; when
FT                                associated with A-64.
FT                                {ECO:0000269|PubMed:15667203,
FT                                ECO:0000269|PubMed:17330962,
FT                                ECO:0000269|PubMed:19170619}.
FT   MUTAGEN      67     67       N->L: Reduced activity.
FT                                {ECO:0000269|PubMed:15667203,
FT                                ECO:0000269|PubMed:17330962,
FT                                ECO:0000269|PubMed:19170619}.
FT   MUTAGEN      67     67       N->Q: Normal activity.
FT                                {ECO:0000269|PubMed:15667203,
FT                                ECO:0000269|PubMed:17330962,
FT                                ECO:0000269|PubMed:19170619}.
FT   MUTAGEN      94     94       H->C,D,E,N,Q: Strongly reduced CO(2)
FT                                hydrase and p-nitrophenyl acetate
FT                                esterase activities, impaired stability
FT                                of zinc binding.
FT                                {ECO:0000269|PubMed:8431430,
FT                                ECO:0000269|PubMed:9398308}.
FT   MUTAGEN     106    106       E->A,Q: Strongly reduced CO(2) hydrase
FT                                activity. {ECO:0000269|PubMed:15299482,
FT                                ECO:0000269|PubMed:7901850}.
FT   MUTAGEN     106    106       E->D: Normal CO(2) hydrase activity.
FT                                {ECO:0000269|PubMed:15299482,
FT                                ECO:0000269|PubMed:7901850}.
FT   MUTAGEN     117    117       E->Q: Strongly reduced activity and
FT                                sulfonamide affinity.
FT                                {ECO:0000269|PubMed:8639494}.
FT   MUTAGEN     119    119       H->D,N,Q: Reduced activity.
FT                                {ECO:0000269|PubMed:9398308}.
FT   MUTAGEN     119    119       H->E: Strongly reduced activity.
FT                                {ECO:0000269|PubMed:9398308}.
FT   MUTAGEN     121    121       V->A,G,I,L,S: Reduced CO(2) hydrase and
FT                                p-nitrophenyl acetate esterase
FT                                activities. {ECO:0000269|PubMed:1910042}.
FT   MUTAGEN     121    121       V->K,R: Strongly reduced CO(2) hydrase
FT                                and p-nitrophenyl acetate esterase
FT                                activities. {ECO:0000269|PubMed:1910042}.
FT   MUTAGEN     142    142       V->F,Y: Strongly impaired activity.
FT                                {ECO:0000269|PubMed:1932029}.
FT   MUTAGEN     142    142       V->G: Weakly impaired activity.
FT                                {ECO:0000269|PubMed:1932029}.
FT   MUTAGEN     142    142       V->H: Impaired activity.
FT                                {ECO:0000269|PubMed:1932029}.
FT   MUTAGEN     197    197       L->A: Reduced CO(2) hydrase activity.
FT                                {ECO:0000269|PubMed:8485129}.
FT   MUTAGEN     197    197       L->E,H,R: Strongly reduced CO(2) hydrase
FT                                activity. {ECO:0000269|PubMed:8485129}.
FT   MUTAGEN     197    197       L->F: Normal activity.
FT                                {ECO:0000269|PubMed:8485129}.
FT   MUTAGEN     198    198       T->A,C,H,P: Strongly reduced activity.
FT                                {ECO:0000269|PubMed:12056894,
FT                                ECO:0000269|PubMed:7761440,
FT                                ECO:0000269|PubMed:7901850,
FT                                ECO:0000269|PubMed:8262987,
FT                                ECO:0000269|PubMed:8399159}.
FT   MUTAGEN     198    198       T->D,E: Strongly reduced activity, but
FT                                enhanced zinc affinity.
FT                                {ECO:0000269|PubMed:12056894,
FT                                ECO:0000269|PubMed:7761440,
FT                                ECO:0000269|PubMed:7901850,
FT                                ECO:0000269|PubMed:8262987,
FT                                ECO:0000269|PubMed:8399159}.
FT   MUTAGEN     198    198       T->S,V: Reduced activity.
FT                                {ECO:0000269|PubMed:12056894,
FT                                ECO:0000269|PubMed:7761440,
FT                                ECO:0000269|PubMed:7901850,
FT                                ECO:0000269|PubMed:8262987,
FT                                ECO:0000269|PubMed:8399159}.
FT   MUTAGEN     199    199       T->H: Higher affinity for bicarbonate.
FT                                Enhanced proton transfer capacity; when
FT                                associated with A-64.
FT                                {ECO:0000269|PubMed:16106378,
FT                                ECO:0000269|PubMed:1909891,
FT                                ECO:0000269|PubMed:8451242}.
FT   MUTAGEN     199    199       T->S: Enhanced p-nitrophenyl acetate
FT                                esterase activity, but normal CO(2)
FT                                hydrase activity.
FT                                {ECO:0000269|PubMed:16106378,
FT                                ECO:0000269|PubMed:1909891,
FT                                ECO:0000269|PubMed:8451242}.
FT   MUTAGEN     201    201       P->A: Normal CO(2) hydrase activity, but
FT                                impaired stability.
FT                                {ECO:0000269|PubMed:8218160}.
FT   CONFLICT    179    180       DP -> AA (in Ref. 6; AAH11949).
FT                                {ECO:0000305}.
FT   TURN          9     11       {ECO:0000244|PDB:3K34}.
FT   TURN         13     15       {ECO:0000244|PDB:3K34}.
FT   HELIX        16     18       {ECO:0000244|PDB:3K34}.
FT   HELIX        21     24       {ECO:0000244|PDB:3K34}.
FT   STRAND       25     27       {ECO:0000244|PDB:3K34}.
FT   STRAND       31     33       {ECO:0000244|PDB:2X7S}.
FT   TURN         35     37       {ECO:0000244|PDB:3K34}.
FT   STRAND       38     40       {ECO:0000244|PDB:3KS3}.
FT   STRAND       42     44       {ECO:0000244|PDB:3KOI}.
FT   STRAND       45     50       {ECO:0000244|PDB:3K34}.
FT   STRAND       56     61       {ECO:0000244|PDB:3K34}.
FT   STRAND       63     70       {ECO:0000244|PDB:3K34}.
FT   STRAND       73     75       {ECO:0000244|PDB:3K34}.
FT   STRAND       77     82       {ECO:0000244|PDB:3K34}.
FT   STRAND       88     97       {ECO:0000244|PDB:3K34}.
FT   STRAND      106    109       {ECO:0000244|PDB:3K34}.
FT   STRAND      115    124       {ECO:0000244|PDB:3K34}.
FT   HELIX       125    127       {ECO:0000244|PDB:3K34}.
FT   HELIX       130    133       {ECO:0000244|PDB:3K34}.
FT   STRAND      139    151       {ECO:0000244|PDB:3K34}.
FT   HELIX       154    156       {ECO:0000244|PDB:3K34}.
FT   HELIX       157    162       {ECO:0000244|PDB:3K34}.
FT   HELIX       163    165       {ECO:0000244|PDB:3K34}.
FT   STRAND      172    174       {ECO:0000244|PDB:3K34}.
FT   HELIX       180    183       {ECO:0000244|PDB:3K34}.
FT   STRAND      190    195       {ECO:0000244|PDB:3K34}.
FT   STRAND      206    213       {ECO:0000244|PDB:3K34}.
FT   STRAND      215    217       {ECO:0000244|PDB:3K34}.
FT   HELIX       219    225       {ECO:0000244|PDB:3K34}.
FT   TURN        226    228       {ECO:0000244|PDB:4QK3}.
FT   STRAND      229    231       {ECO:0000244|PDB:3K34}.
FT   STRAND      233    235       {ECO:0000244|PDB:4Q06}.
FT   STRAND      256    258       {ECO:0000244|PDB:3K34}.
SQ   SEQUENCE   260 AA;  29246 MW;  2EC2BB7548F10558 CRC64;
     MSHHWGYGKH NGPEHWHKDF PIAKGERQSP VDIDTHTAKY DPSLKPLSVS YDQATSLRIL
     NNGHAFNVEF DDSQDKAVLK GGPLDGTYRL IQFHFHWGSL DGQGSEHTVD KKKYAAELHL
     VHWNTKYGDF GKAVQQPDGL AVLGIFLKVG SAKPGLQKVV DVLDSIKTKG KSADFTNFDP
     RGLLPESLDY WTYPGSLTTP PLLECVTWIV LKEPISVSSE QVLKFRKLNF NGEGEPEELM
     VDNWRPAQPL KNRQIKASFK
//
